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Asthma is common disease in child-
hood. Obesity is increasing health 
problem related to asthma. The use 
of inhaled corticosteroids (ICS) for 
childhood asthma has steadily in-
creased. This long term follow-up 
study contains 100 children hospi-
talized for wheezing in infancy and 
followed until 12.3 years of age. In 
the present study, we evaluated the 
association between overweight and 
asthma, allergies and lung function 
and ICS´ effect on bone mineral den-
sity at early teenage in this asthma 
risk group.
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ABSTRACT: 
 
Growing evidence shows that overweight children face increased asthma risk. The link between asthma, 
allergy, lung function, and obesity in children is unclear. Paediatric use of inhaled corticosteroids (ICS) for 
asthma has steadily increased. However, knowledge of long-term safety to bone health is insufficient. 
Between 1991 and 1992, 100 children, aged 1–23 months, hospitalised for wheezing were recruited to an early-
intervention bronchiolitis study. An additional 14 children were recruited and later included in the study 
group. Follow-up visits organised at median ages of 4.0, 7.2, and 12.3 years consisted of medical examinations, 
weight and height measurements, and skin prick tests for common indoor and outdoor allergens. Exercise 
challenge tests were performed to show bronchial hyperreactivity (BHR). At the median age of 12.3 years, 
bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA) and peripheral 
quantitative computed tomography (pQCT). The history of ICS consumption was collected from medical 
records. Cumulative doses and the duration of ICS therapy were calculated. The participation rate was 82/100 
at age 7.2 and 81/100 at age 12.3 years, and 89/114 children attended the BMD study. 
 At 12.3 years of age, 38% of participants were asthmatic, 33% were overweight, and 20% were 
obese. There was no association between previous or current overweight or obesity and asthma or BHR at 7.2 
or 12.3 years of age. The current overweight was associated with decreased FEV1/FVC (forced expiratory 
volume in 1 sec/forced vital capacity) at both 7.2 and 12.3 years of age and reduced flows in small airways at 
12.3 years of age. The results were similar in continuous and categorised analyses, being robust to 
adjustments for viral findings at study entry and asthma medication at school age. 
 During follow-up, 73 children received ICS medication, and 16 did not. The mean cumulative 
ICS dose was 517 mg (in the range of 31–1,813 mg). The cumulative ICS dose was associated with reduced 
BMD measured by DXA in the femoral neck (r = −0.320, r2 = 0.10, adj. p < 0.05), and with a lower total bone (r = 
−0.177, r2 = 0.031; adj. p = 0.016), cortical (r = −0.136, r2 = 0.019, adj. p = 0.019), and trabecular (r = −0.160, r2 = 
0.026; adj. p = 0.036) BMD documented by pQCT in the radius. The lumbar spine BMD and the apparent 
volumetric BMD of femoral neck were reduced when ICS were used regularly before 6 years of age (adj. p < 
0.05). Similar age-specific changes were not found in the radius or the tibia. No significance was found for 
distal tibia. The results remain similar after adjusting with known confounding factors. 
 In conclusion, overweight and obesity were significant risk factors for reduced lung function at 
school age in this asthma-risk group. The present study did not reveal a connection between asthma and 
overweight. The use of ICS during childhood may reduce BMD measured during early teenage years. 
Children suffering from early-life wheezing should avoid excessive weight gain during childhood and use the 
lowest sufficient ICS dose to maintaining adequate asthma control. 
 
National Library of Medicine Classification: WD 210, WD 300, WE 270, WS 288 
Medical Subject Headings: Hypersensitivity; Asthma/Therapy; Bone Density; Bronchial Hyperreactivity; 
Bronchiolitis; Child; Absorptiometry, Photon; Follow-Up Studies; Tomography, x-ray; Obesity; Airway 
Obstruction; Overweight;  Spirometry; Respiratory Sounds 
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TIIVISTELMÄ: 
 
Ylipainoisten lasten astmariski on lisääntynyt, mutta yhdistävät tekijät astman, allergioiden, keuhkojen 
toiminnan ja ylipainon välillä ovat epäselviä. Lasten astman hoidossa hengitettävien kortikosteroidien (ICS) 
käyttö on yleistä. Tiedot ICS-lääkityksen pitkäaikaishaitoista luustolle ovat puutteelliset. Vuosina 1991 - 1992 
aloitettiin seurantatutkimus astman riskitekijöistä varhaisen hengenahdistuksen jälkeen. Tutkimukseen 
rekrytoitiin 100, 1-23 kuukauden ikäistä, sairaalahoitoon hengenahdistuksen takia joutunutta lasta. 
Tutkimuskäynnit totetutuivat 4.0, 7.2 ja 12.3 vuoden keskimääräisessä iässä sisältäen lääkärin tutkimuksen, 
pituuden ja painon mittaukset ja allergiatutkimukset ihopistokokeina. Kouluiässä tutkittiin keuhkojen 
toimintaa ja hyperreaktivisuutta spirometrialla ja juoksurasituskokeella. 12.3 vuoden iässä luustontiheys 
tutkittiin kahdella eri radiologisella menetelmällä: Dual energy x-ray absobtiometryllä (DXA) ja perifeerisellä 
kvantitatiivisella tietokonetomografialla (pQCT). ICS-kokonaisannokset ja käyttöaika laskettiin haastatelujen 
ja sairaskertomusten perusteella. Luustontiheys tutkimukseen kutsuttiin mukaan 14 lasta, jotka oli rekrytoitu 
mukaan tutkimukseen, mutta jotka eivät osallistuneet alun hoitotutkimukseen. 
 Seurantakäynneille osallistui 82/100 lasta 7.2 vuoden iässä, 81/100 lasta 12.3 vuoden iässä ja 
89/114 lasta osallistui luustotutkimukseen 12.3 vuoden iässä. Lapsista 38% oli astmaatikkoja, 33% ylipainoisia 
ja 20% lihavia. Astmalla tai keuhkojen hyperreaktiivisuudella ja tutkimushetken ylipainolla 12.3 tai 7.2 
vuoden iässä ei todettu keskinäistä yhteyttä. Tutkimushetken ylipainolla todettiin yhteys alentuneeseen 
(nopean uloshengityksen vitaalikapasiteetin ja uloshengityksen sekuntikapasiteetin suhteeseen (FEV1/FVC) 
spirometriassa 7.3 ja 12.3 vuoden keskimääräisessä iässä. Pienten ilmateiden virtaus todettiin matalammaksi 
ylipainoisilla lapsilla 12.3 vuoden iässä. Todetut yhteydet säilyivät merkittävinä myös vakioitaessa analyysi 
varhaisen hengenahdistuksen virusetiologialla ja astmalääkityksellä kouluiässä. Seurannan aikana 73 lasta sai 
jaksoittain ICS-lääkitystä, 16 lasta ei saanut tutkimusaikana ICS-lääkitystä. Keskimääräinen 
kokonaislääkeannos oli 517mg (vaihteluväli 21-1813mg). ICS-annoksen ja reisiluunkaulan matalamman 
luuntiheyden (DXA) välillä todettiin yhteys (r = −0.320, r2 = 0.10, vakioitu. p < 0.05). Myös ICS-annoksen ja 
matalamman radiuksen (pQCT) kokonaisluuntiheyden (r = −0.177, r2 = 0.031; vakioitu. p = 0.016), kortikaalisen 
(r = −0.136, r2 = 0.019, vakioitu. p = 0.019) ja trabekulaarisen (r = −0.160, r2 = 0.026; vakioitu. p = 0.036) välillä 
todettiin yhteys. Lannerangan luuntiheys (DXA) oli matalampi niillä lapsilla, joilla ICS-lääkitys oli totetunut 
säännöllisesti vain alle 6-vuotiaana (vakioitu. p < 0.05). Käyttöikään sidonnaisia muutoksia ei todettu 
radiuksessa tai tibiassa. Tibian osalta merkittäviä yhteyksiä luustontiheyden ja ICS-lääkityksen osalta ei 
löydetty. Tulokset säilyivät samanlaisina tunnetuilla sekoittavilla tekijöillä vakioimisen jälkeen. 
 Yhteenvetona voidaan todeta ylipainon ja lihavuuden olevan merkittävä riskitekijä 
alentuneelle keuhkojen toiminnalle kouluiässä niillä lapsilla joilla on jo suurentunut astmariski. Tämä 
tutkimus ei osoittanut yhteyttä astman ja ylipainon välillä. Varhaisen hengenahdistuksen jälkeen 
normaalipainoon pyrkiminen edistää keuhkojen toimintaa. Lapsuudessa käytetty ICS-lääkitys voi vaikuttaa 
luustontiheyteen myöhemmässä kouluiässä ja nuoruudessa. Astmalääkitystä tarvitsevilla lapsilla tulee pyrkiä 
aktiivisesti pienimpään ICS-annokseen, millä hoitotasapaino säilyy hyvänä. 
 
Yleinen Suomalainen Asiasanasto: Allergia; Astma; Bronkioliitti; Keuhkot; Luusto, Lapset; Lihavuus; Lääkehoito; 
Seurantatutkimus; Spirometria; Suomi; Ylipaino 
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1 Introduction 
Wheezing illnesses during childhood are common and well-known risk factors for the 
later onset of asthma (1-3). There are several phenotypes of wheezing (3). The increasing 
prevalence of obesity has introduced new phenotype, obesity-induced wheezing, and later 
obesity-related asthma (4). The connection between overweight and asthma has been 
confirmed in epidemiological studies and meta-analyses (5,6). Overweight has an 
independent mechanical effect on lung function (5), and it may decrease lung compliance 
(7). In children, studies have shown that there are also benefits to lung function from 
weight gain (8), depending on the age during admission (9). Allergic diseases, like atopic 
dermatitis, have been associated with overweight (10), however with conflicting results 
(11). The mechanism may be different from the eosinophilic inflammation seen in allergic 
asthma, because obesity increases more the risk for non-atopic asthma (12). Asthma, lung 
function, and allergy are all related to overweight, but the interactions and causalities are 
still unknown. 
Inhaled corticosteroids (ICS) are recommended widely as the first line of 
therapy for asthma (13,14), and the benefits of ICS treatment are undeniable (15). Growth 
retardation is the most monitored side effect of ICS medication, lately shown to cause only 
minor effects on adult height (16). Although safer than systemic corticosteroids, ICS can 
potentially cause detrimental effects on bone health (17). In clinical trials and follow-up 
studies, ICS have been safe for bone mineral density (BMD) (18-20). In childhood asthma, 
ICS medication could be long lasting and continue throughout rapid growth periods in 
early childhood and teenage years when BMD accretion is also rapid (21). The long-term 
consequences of decreased BMD accretion in childhood and adolescence are not known. 
Dual-energy x-ray absorptiometry (DXA) and peripheral quantitative computed 
tomography (pQCT), both low in radiation, are accepted methods of measuring BMD in 
children (22). There are references for paediatric BMD measured with DXA but not with 
pQCT, but the threshold describing significantly low BMD is not known for either method 
(23,24). 
The purpose of the present study was to evaluate the effect of overweight on 
asthma, allergies, and lung function in children known to have a higher asthma risk after 
severe early childhood wheezing and to assess the impact of ICS on BMD at the median 
age of 12.3 years. 
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2 
 
2 Review of the Literature 
 
2.1 WHEEZING ILLNESSES IN CHILDHOOD 
The aetiology of wheezing in early childhood is multifactorial, including virus infections, 
allergies, and environmental factors (2,25). Bronchiolitis is the most common acute illness 
and cause of hospitalisation in infancy (26). According to American and British guidelines, 
bronchiolitis is the first respiratory viral infection with symptoms and signs of respiratory 
effort and wheezing in children less than 2 years of age (27,28). 
 The prevalence of bronchiolitis during the first year of life is 18%–32% and 
9%–17% during the second year (3,27,29). The hospitalisation rate is 1%–3%; 
hospitalisation is highest among babies less than 6 months of age (30). A respiratory 
syncytial virus (RSV) is the most common virus resulting in hospitalisation (31,32), and 
another common aetiology of bronchiolitis in older children is a human rhinovirus, a 
known risk factor for later asthma (33). 
 Some of the children diagnosed with bronchiolitis in infancy suffer episodic 
wheezing during childhood, and some of them are diagnosed with asthma later (34). 
Because of the heterogeneity in the aetiology of wheezing, the diagnosis of bronchiolitis is 
used only for children less than 12 months of age in some studies (25,35) and clinical 
guidelines (36,37). Actually, the first classification of acute respiratory infections in 
children defined bronchiolitis as being diagnosed to children under 6 months of age (38). 
2.2 ASTHMA IN CHILDHOOD 
2.2.1 Worldwide prevalence 
Asthma is a chronic inflammatory disease with variable airflow obstruction and bronchial 
hyper responsiveness. Symptoms include recurrent episodes of wheezing, shortness of 
breath, and cough (13). Asthma prevalence has increased since the 1970s (39). 
 According to the International Study of Asthma and Allergies in Childhood 
(ISAAC), the prevalence of asthma in children 6–7 years of age varies from 4% in Northern 
and Eastern Europe up to 29% in Oceania and in teenagers 13–14 years of age from 5% to 
22% in the respective regions (40). Further, asthma prevalence in English-speaking centres 
was 28% in childhood and 20% in teenage years (40). During the last 10 years, the 
prevalence of asthma symptoms has slightly decreased or reached a plateau in Western 
countries (41,42). 
 Asthma prevalence figures from Finland are old. The prevalence has been 
between 4%–8% in 13- to 14-year-old adolescents (43). In the Kuopio region, the lifetime 
prevalence of asthma in a population-based study has been estimated to be 4% in 7- to 12-
year-old children (44). 
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2.2.2 Asthma phenotypes and epidemiological risk factors for asthma 
Childhood asthma is a multi-origin disease. Several phenotypes have been illustrated with 
different origins, severities, treatments and outcomes, as summarised in recent reviews 
(13,45). The common phenotypes described for wheezing and asthma during childhood 
are early-onset transient, early-onset persistent and late-onset wheezing (45). 
Classifications into virus-induced, allergy-induced, multi trigger, exercise-induced, and 
obesity-related have also been used (13). 
In the longitudinal birth cohort studies, the major risk factors for asthma and 
wheezing include the parents’ history of asthma, the child´s atopy or atopic dermatitis in 
the first year of life, other allergic diseases, and maternal smoking during pregnancy 
(2,29,45-48). In cross-sectional paediatric studies, risk factors have been similar (3,46), and 
they have emphasised the role of early immunoglobulin E (IgE) sensitisation in later 
wheezing symptoms (3). 
The late onset of wheezing, at over 3 years of age, has been associated with 
increased asthma risk (47). Persistent wheezing has been associated with abnormalities in 
lung function in children 6 years of age, which could lead to asthma in adulthood (49). The 
virus infections in the first years of life, especially RSV and rhinovirus infections are risk 
factors for asthma (33,50-52). Rhinovirus infections are also associated with asthma 
exacerbations at all ages (53). 
 Recently, genetic, nutritional and environmental factors have been new 
focuses of asthma studies (54,55). 
2.3 GUIDELINES TO THE DIAGNOSIS AND MANAGEMENT OF 
BRONCHIOLITIS AND CHILDHOOD ASTHMA 
2.3.1 Diagnosis and management of bronchiolitis 
There is neither an explicit diagnostic tool for bronchiolitis (26) nor consensus about 
treatment; therefore, the care of patients varies between hospitals (56). The national and 
international guidelines recommend that diagnosis of bronchiolitis should be based on 
current epidemiologic data and clinical examination; laboratory tests and a chest x-ray 
should not routinely be taken (27,57). 
 Management of bronchiolitis should include monitoring whether oxygen 
supply and proper hydration are needed (27,57). Bronchodilators should not be used 
routinely and should be continued only if there is a positive response. The routine use of 
corticosteroids should also be avoided (27). Although there is evidence showing that oral 
dexamethasone together with inhaled adrenaline could shorten the length of 
hospitalisation (36). A meta-analysis demonstrated the effectiveness of inhaled adrenaline 
alone for bronchiolitis (58), but a recently published large double blind study showed a 
uniform effect between racemic adrenalin and NaCl inhalations, and an on-demand 
medication was more beneficial compared to the fixed schedule (59). Inhaled hypertonic 
saline is a promising new therapy (36). For severe bronchiolitis, nasal continuous positive 
airway pressure (NCPAP) has been used successfully, and it might decrease the need of 
intubation and ventilation in small babies (60). 
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2.3.2 Diagnosis and management of childhood asthma  
There are national and international recommendations for the diagnosis and management 
of childhood asthma (13,14,61). In the Finnish guidelines, asthma can be clinically 
diagnosed in small children if they have had three wheezing episodes in a 1-year period, 
and there are one or more risk factors for asthma (i.e., atopic disease or parental asthma 
exists) (14). From 3 years of age, in both national and international guidelines, tests 
showing abnormal lung function are recommended, and for school-aged children, it is 
compulsory to perform spirometry and/or an exercise challenge test (ECT) for asthma 
diagnosis (14,61,62). 
 ICS are the recommended first line of therapy for asthma in children and 
adults (13,14,15). The use of ICS has improved symptom control in asthma and decreased 
hospitalisation for asthma in children (15,34,63,64). Aside from and combined with ICS, 
montelukast and short- and long-acting β-agonists are used for asthma medication in 
children (13,14,34). ICS potentially cause side effects, and on the other hand, the common 
reason for treatment failure is compliance; therefore, it is important to optimise ICS 
treatment in children (65). There is evidence that the early treatment with anti-
inflammatory therapy could prevent irreversible airway injury and improve lung function 
(65,66). 
2.4 ASSOCIATION BETWEEN ASTHMA, LUNG FUNCTION, ALLERGY AND 
OVERWEIGHT IN CHILDHOOD 
2.4.1 Definitions of overweight and obesity 
The established definitions of overweight and obesity in adults are BMI > 25 for 
overweight and BMI > 30 for obesity. The definition is more complex for growing children. 
Age- and sex-specific BMI cut-offs based on national references are advisable to use. If 
such national references are not available, international references can be used, but that 
approach is less reliable (7,67). Based on international surveys, BMI > 91st percentile has 
been used to define overweight and BMI > 98th percentile to define obesity, corresponding 
with BMI > 25 and BMI > 30 in young adults (7,67). Definitions vary in different studies. 
For example, BMI > 95th percentile has been used as a cut-off point for overweight (68,69). 
In the United States, the recommended cut-off points (70) are BMI > 85th percentile for 
overweight and BMI > 95th percentile for obesity, which have been used in some studies 
(69,71). The BMI percentiles can be expressed as age- and gender-specific BMI standard 
deviation scores (BMI-SDS), also called z-scores. 
 Waist circumference (WC), waist–hip ratio (WHR), or skinfold thickness can 
be used to estimate overweight and body fat content (72,73). WC has been correlated 
nearly completely with age- and sex-specific BMI in children (74). Scanning methods and 
bioelectrical impedance are used to measure body fat in studies (73), but not in clinical 
practice. 
2.4.2 Epidemiology of overweight and obesity in childhood  
The prevalence of overweight and obesity is increasing in Europe (75) and worldwide 
(68,69). In Europe, the prevalence of overweight varies from 10% to 36% in 7- to 11-year-
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old children and from 8% to 23% in 14- to 17-year-old children (75). In the United States, a 
plateau in the increase of overweight and obesity was reached in the 20th century (76), and 
the prevalence of overweight among adolescents has stayed between 16% and 17% (69). 
There is strong tracking with increased BMI from childhood and adolescence to adulthood 
(77,78). 
 The latest prevalence figures from Finland are from 2006. At that time, 9.8% of 
5-year-old boys were overweight, and 2.5% were obese. The figures were 17.7% and 2.5%, 
respectively, for girls at the same age (79). At 12 years of age, the prevalence of overweight 
was 23.6% and obesity 4.7% in boys, and 19.1% and 3.2% in girls, respectively (79). In the 
Finnish birth cohort studies, combined information shows a trend of increased BMI in 12- 
to15-year-old boys and in 12-year-old girls (80). 
2.4.3 Obesity-related illnesses in childhood 
Overweight is a growing public health issue in childhood and adolescence (72,81). Obesity 
and overweight have been associated with poorer overall health, psychosocial health, as 
well as health-related quality of life (81-83). Further, overweight increases health care 
utilisation (84). 
 Overweight has been associated with low-grade inflammation, which was 
thought to be the link between obesity and metabolic syndrome (85). Type 2 diabetes is 
associated with obesity in adults and in children (72,86). The prevalence of non-alcoholic 
fatty liver disease is increased among overweight adolescents (87). Asthma and other 
respiratory illnesses and their symptoms are commonly associated with overweight 
(81,84). Childhood obesity is a risk factor for cardiorespiratory diseases and is associated 
with high blood pressure (88-91). 
2.4.4 Lung function and overweight 
Obesity causes mechanical changes in the airways, where the elasticity of the chest wall 
decreases, and the airway resistance increases (7). Obesity could lead to airway smooth 
muscle contraction, which induces restriction and impairment of lung function (5). In 
adults, obesity decreases total lung capacity (TLC), tidal volume (TV), expiratory reserve 
volume (ERV), functional residual capacity (FRC), and forced expiratory volume in 1 sec 
(FEV1) (5,7,92,93). Peripheral airway obstruction due to obesity has been documented by 
decreased flows at 50% of forced vital capacity (FVC) (MEF50) (93). Overall, it can be said 
that the restrictive pattern of lung function disorder has been more characteristic in obesity 
than the obstructive pattern. 
 In healthy obese children, the influence of obesity has been complex. In a 
Chinese survey, lung function was studied in 2,179 schoolchildren at the median age of 10 
years. Among them, asthma-presumptive symptoms were more common in obese 
children, but in spirometry, FEV1 actually increased (94). In line with this, overweight had 
a beneficial effect on lung function in healthy 7- to 20-year-old girls in another study (8). In 
a Taiwanese study, lung function and bronchial hyperreactivity (BHR) were measured in 
1,459 teenagers, and there was a decreased risk for BHR in the lowest BMI groups (95). In 
a population study of 5,993 children aged 7–12 years, all variables in the spirometry were, 
irrespective of BMI, within normal limits. But FEV1 and FVC in the lowest BMI quintile 
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were significantly lower than in other quintiles (96). No associations between BHR and 
BMI were found, but asthma and atopy were associated with high BMI in girls (96). In the 
other population study, lung function improved when weight increased in healthy 8- to 
11-year-old children, but beyond that age, lung function first reached a plateau and then 
decreased among the obese youths (9). 
 Childhood weight can affect lung function in adulthood. In a Danish 
longitudinal population-based study, 193 obese and 205 non-obese men were studied, and 
their age-adjusted FVC and FEV1 were compared against birth weight, weight at 7 and 13 
years of age, and current weight (97). Weight at 7 years of age was positively correlated 
with FEV1 and FVC in an analysis adjusted for current weight, smoking, and education. 
Current overweight was strongly associated with decreased lung function in an adjusted 
linear regression (97). 
 The exercise capacity of obese children is impaired; they have increasing 
breathing effort and more dyspnoea (5). In healthy pre-teenagers, body fat has predicted 
airways narrowing after exercise (98). In addition, overweight children have more 
behavioural problems, and they are physically less active (99). 
2.4.5 Asthma and overweight; mechanism  
The epidemics of asthma and obesity have proceeded concomitantly, and plenty of studies 
have evaluated the association between them. There is a consensus on the link between 
obesity and asthma or respiratory symptoms (5). A meta-analysis from cohort studies 
concluded that children with higher body weight are at greater risk for future asthma (6). 
 Obesity has been associated with more severe asthma symptoms (100-102) 
and reduced responses to asthma medication (103), leading to an increased use of 
medication (104). Birth weight has been associated with increased asthma risk at teenage 
years (105,106), but this is not so in all studies (107). In adults, weight loss has lessened 
asthma symptoms (108) and improved lung function in asthmatic patients (109). 
 Former studies have discussed whether obesity-related asthma is an own 
asthma phenotype—asthma with non-eosinophilic inflammation and decreased response 
to conventional asthma treatment (4,110). 
 The mechanism between obesity and asthma or lung function disorder in 
children is multifactorial (Figure 1). There is some evidence that asthma and obesity might 
share the same origins in early childhood (111). Common genes have been found for both 
conditions (100). Early-life factors like nutrition during pregnancy, an early childhood 
sedentary lifestyle, and exercise habits later might have an influence on both obesity and 
asthma (5,111). The other proposed mechanisms between overweight and asthma are 
reduced chest wall compliance, systemic inflammation, insulin resistance, and co-
morbidities like gastro-oesophageal reflux or common genetic aetiology (5). 
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Figure 1. Mechanisms between obesity, asthma and lung function in children, according to 
Jensen 2012 (112). Common factors can lead obesity and asthma; in obese children increased 
lean mass improves lung development and increased fat mass causes negative effects on lungs 
via complex pathways. 
 
Obesity leads to low-grade inflammation and the increase of adipokines and other obesity-
related inflammatory mediators (5). Leptin, one of the adipokines, has been assumed to 
modulate the connection between obesity and asthma (113), being associated with both 
non-atopic (114) and atopic asthma (115). Results on other inflammatory mediators vary: 
resistin had a negative association with asthma in one study (116), and low adiponectin 
levels have been associated with an increased risk of allergic diseases and asthma (114), 
but another study found no association (117). 
 The asthma symptoms related to obesity have not been associated with BHR 
(100,118,119), or the results have been conflicting (119,120). Also, in studies where the 
association between asthma and obesity has been evaluated together with atopic 
sensitisation, the results for atopic sensitisation have been mostly negative (121,122). In 
adults, obese asthmatics have had lower exhaled nitric oxide (FEno) and sputum eosinophil 
levels (123). It is unlikely that allergic inflammation is the basis of the asthma-obesity 
relation (12,121). 
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 Obesity affects lung function itself and modifies the asthma-obesity 
connection. This topic is discussed further in detail in section 3.4. Other lung-related 
diseases like sleep-disordered breathing might also have an effect on obesity-related 
asthma (124). 
 Age could be one modifying component in the asthma-obesity relation in 
children, and it seems that the influence of obesity is more notable in younger children 
(125,126). Sex and race might modify the relation between asthma and obesity, but the 
results are too conflicting to confirm the association (104,119,127-131). 
2.4.6 Asthma and overweight studies 
Birth cohort studies 
There are six large birth cohort studies evaluating the asthma-obesity relation in children. 
The most recent prospective birth cohort study from Brazil followed 4,439 children aged 
10–11 and 14–15 years (132). They assessed asthma symptoms with an ISAAC 
questionnaire in both follow-up times. The prevalence of wheezing at 15 years of age and 
persistent wheezing at both 11 and 15 years of age was higher in obese children in 
adjusted analysis. The results were similar when obesity was measured with skinfold 
thickness (132). An Australian study found a significant association between the BMI z-
score at 14 years of age and a change in the z-score from 5 to 14 years of age and parent-
reported asthma, but the weight at 5 years of age did not predict asthma at 14 years of age 
(133). The National Longitudinal Survey of Youth (NLSY), with a 14-years of follow-up 
time, found an increased risk for asthma in boys—but not in girls—who were overweight 
(BMI > 85th percentile) at 2–3 years of age or during the whole follow-up time (134). In 
another cohort, BHR was measured, and they reported an association between persistent 
or current high BMI and dyspnoea or BHR at 8 years of age (120). An earlier high BMI, if it 
has become normal, was not a risk factor for either dyspnoea or BHR (120). Wheeze, 
asthma, and atopy were associated with BMI in females in one birth cohort study (127). 
 Under school age, the risk of getting asthma diagnosis was increased in 
overweight (> 85th percentile) and obese (> 95th percentile) children, especially in boys, 
and in non-atopic children (135). In the birth cohort study of children with a high genetic 
asthma risk, obesity at 1 year of age decreased asthma risk at 6 and 8 years of age, but 
being overweight at 5 years of age increased asthma risk (136). 
Population-based cohort studies 
A large population-based study from the United States used medical records to collect 
weight and height details and asthma diagnoses from 681,122 children at 6 to 19 years of 
age, and 10.9% of children currently had asthma (104). Overweight and obese children had 
higher asthma risk, and increasing weight was associated with increased corticosteroid 
use and emergency department visits (104). Greek schoolchildren, 6–11 years of age were 
studied in a cohort of 2,715 children; BMI > 85th percentile was an independent risk factor 
for asthma, but only in girls (131). A low birth weight was associated with asthma risk and 
overweight or obesity later in life amplified the risk of asthma in both girls and boys in a 
large study among junior high school students in Taiwan (106). 
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2.4.7  Lung function and overweight studies 
Epidemiologic, birth cohort, cross-sectional, and case-control studies have been done to 
find out how obesity modifies lung function in asthmatic children and adults. There is a 
relation between asthma and obesity, but when pulmonary function and bronchial 
reactivity were studied objectively, the results were mainly negative. 
Birth cohort studies 
In the Tucson Children’s Respiratory Study (a birth cohort of 1,246 children), lung 
function, bronchodilator response, and peak expiratory flow variation were studied at 11 
years of age, and respiratory symptoms and weight status were measured at 6 and 11 
years of age (119). An association was revealed between weight gain before puberty and 
an increased risk of new asthma diagnoses and BHR at 11 years of age (119). In another 
birth cohort study from New Zealand, high BMI was associated with asthma and atopy, 
but inversely associated with FEV1/FVC in 9- to 26-year-old females, and no association 
between weight and BHR was found (127). 
Clinical trials and case-control studies 
A large clinical trial, Childhood Asthma Management study (CAMP), found an association 
between higher BMI and increased FVC and FEV1, but decreased FEV1/FVC ratio (144). In 
a later analysis from the CAMP study, lung function reduction was also associated with a 
decreased response to inhaled budesonide in overweight and obese children compared 
with normal-weight asthmatic children (103). 
A case-control study from Italy compared lung functions of 118 pre-pubertal 
children; the groups were obese asthmatic, normal-weight asthmatic, obese non-asthmatic, 
and normal-weight non-asthmatic children (145). Asthma had an independently 
significant association with lung function and airway inflammation. Obesity was related 
to PEF and MEF75 in a multivariate analysis, but obesity and BRH were not related. FEno 
was significantly higher in asthmatic children, but was also increased in obese non-
asthmatic children compared with normal-weight non-asthmatic children, suggesting the 
presence of obesity-induced pro-inflammatory changes (145). Another study with similar 
groups of 7- to 11-year-old children performed the pulmonary function test in 120 
children, and obese asthmatic patients had the lowest FEV1/FVC ratio when compared 
with other groups (110). In an adult study, lung function was reduced in patients with 
asthma and obesity, and in addition, FVC and FRC were also reduced in obese non-
asthmatic adults (146). 
Cross-sectional and cohort studies 
Recently, a cross-sectional French study explored the relation of weight status and asthma 
characteristics in 491 asthmatic children aged 6–15 years (147) and found a positive 
association between weight and FVC or FEV1 in females, but overweight and obese 
children had reduced TLC and residual volume/TLC (147). 
In a large population-based study from Israel, obese children wheezed more 
frequently, and asthma diagnoses were more common among them, but no association 
between overweight or obesity and lung function was found (148). In fact, BHR was more 
13 
common among non-obese asthmatic children compared with obese asthmatic children 
(148). In another study, peak expiratory flow rates (PEFR) from 1,322 asthmatic children 
aged 4–9 years were similar in obese (> 95th percentile) and normal-weight children, but 
obese children had more symptoms, emergency hospital visits, and oral corticosteroids 
intake (149). In a Greek schoolchildren cohort, a high BMI was an independent risk factor 
for asthma and atopy. In addition, FVC, FEV1, MEF25–75%, and FEV1/FVC were reduced 
in overweight (> 85th percentile) children, but no difference was found between asthmatic 
and non-asthmatic children (131). In an asthma referral population, no differences were 
found in lung function between obese and normal-weight 4- to 18-year-old children (150). 
In adults, obese (BMI > 30) patients with difficult-to-treat asthma had higher 
FEV1% and lower FRC/TLC% than non-obese patients, with no correlation between 
obesity and FEno (123). Also, an epidemiological study failed to show any association 
between obesity and obstruction or BHR in a population where weight and asthma and 
airway symptoms were associated with one another (151). 
In summary, overweight might have an independent effect on lung function, but studies 
are too controversial to make any final conclusions. Obesity seems not to provoke BHR in 
children. 
2.4.8 Allergic diseases and overweight; mechanism 
Allergy and overweight have increased concomitantly like asthma and overweight, but 
the connection is less studied. Allergic diseases were surveyed in the ISAAC study (152). 
The trends in prevalence of allergic diseases varied and allergic rhinitis/rhinoconjunctivitis 
(AR) and atopic dermatitis (AD) have increased more than asthma in the last decade (152). 
AR prevalence in Europe varies between 2.9%–10% in younger children and between 
4.5%–20% in teenagers, and AD prevalence varies between 2.5%–22% and 2%–15.6%, 
respectively (152). 
There are studies where atopy or allergic diseases are associated with 
overweight (95,96,127,131,153), but several studies have not been able to confirm the 
association (120,139,154,155). High BMI has not been an independent risk factor for allergy 
when adjusted with asthma (121,122). The connection between allergic diseases and 
obesity is complex and dependent on age (10) and sex (11,139). The increased eosinophilic 
inflammation due to overweight is probably not the main mechanism between atopy and 
overweight (12). 
Fat tissue produces inflammatory mediators; these changes in inflammatory 
mechanism have been assumed to explain the relation between overweight and allergic 
diseases like overweight and asthma association. In a large German study, low 
adiponectin levels and symptoms of AD and diagnosed AD correlated, whereas high 
leptin was associated with higher incidence of non-allergic asthma, but no associations 
were found between adipokines and hay fever or AR (114). 
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common among non-obese asthmatic children compared with obese asthmatic children 
(148). In another study, peak expiratory flow rates (PEFR) from 1,322 asthmatic children 
aged 4–9 years were similar in obese (> 95th percentile) and normal-weight children, but 
obese children had more symptoms, emergency hospital visits, and oral corticosteroids 
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2.4.8 Allergic diseases and overweight; mechanism 
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AR prevalence in Europe varies between 2.9%–10% in younger children and between 
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association (120,139,154,155). High BMI has not been an independent risk factor for allergy 
when adjusted with asthma (121,122). The connection between allergic diseases and 
obesity is complex and dependent on age (10) and sex (11,139). The increased eosinophilic 
inflammation due to overweight is probably not the main mechanism between atopy and 
overweight (12). 
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diseases like overweight and asthma association. In a large German study, low 
adiponectin levels and symptoms of AD and diagnosed AD correlated, whereas high 
leptin was associated with higher incidence of non-allergic asthma, but no associations 
were found between adipokines and hay fever or AR (114). 
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2.4.9 Allergy and overweight studies 
Population-based studies 
In the large National Health and Nutritional Examination Survey (NHANES) 2005–2006 
from a cohort of over 4,000 children, overweight and obesity were associated with higher 
IgE levels, and atopy and food allergies increased among obese children (153). A Japanese 
questionnaire study found conflicting results; in 50,086 non-selected schoolchildren, 
obesity was related to higher atopic sensitization and AD prevalence, but lower BMI was 
related to higher AR and atopic conjunctivitis prevalence and the association was stronger 
in boys (11). A third large population study was done in Belgium in 1,576 non-selected 
schoolchildren, where atopic sensitization was increased among underweight girls, but no 
association was found between obesity and allergic respiratory symptoms, AD, or AR 
(139). When clinical data of 5,999 children from seven epidemiological studies were 
combined, a significant association was found between allergy and overweight, but only 
in girls (96). 
Case-control and longitudinal birth cohort studies 
In a practice-based case-control study, 414 children and adolescents with AD were 
compared with 828 healthy controls aged 1–21 years during a 7-year follow-up time (10). 
Early childhood obesity, starting before 5 years of age, and prolonged obesity in childhood 
was risk factors for AD, and obesity was associated with more severe AD (10). 
The longitudinal birth cohort follow-up study also found an association 
between weight gain and AD at 5 and 8 years of age, but no association between BMI and 
sensitisation in prick test was found (154). In a birth cohort study from New Zealand, 1,000 
individuals were followed until 9–26 years of age, and an association was found between 
higher BMI and allergy in females, but not in males (127). 
Cross-sectional studies 
In a multi-centre cross-sectional study of 15,454 young adults from Europe, Australia, 
New Zealand, and the United States, obesity was not associated with AR or with atopic 
sensitization (155). In a cross-sectional Taiwanese study of 1,459 high school children, 
highest BMI quintiles had an increased risk for atopy (positive skin prick tests) and AR in 
adjusted analysis, but only for females (95). The more recent Taiwanese study of 
unselected schoolchildren reported a high prevalence of AR (47.8%) and eczema (10.8%) 
and atopic sensitization (57.3%) measured by IgE levels (156). Allergic diseases were more 
common among boys, and eczema incidence was slightly increased in obese children 
(156). 
In Summary, the connection between obesity and AD has been documented, 
but for other atopic diseases, the results have varied. 
2.5 BONE MINERAL DENSITY IN CHILDHOOD 
2.5.1 Bone development during childhood and adolescence 
Infancy and puberty are times of rapid bone accretion during childhood (21). Bones grow 
in size in parallel with BMD accrual (157). Bone mineralisation with the modelling and 
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remodelling process is essential for normal bone growth (158). The peak bone mass (PBM) 
is gained mostly during teenage years (159). The most rapid increase of BMD is at Tanner 
stages 4 and 5, and bone mass accretion continues over puberty (21,160). It has been 
estimated that 40%–62% of BMD is genetically determined (161). Normal skeletal 
development and bone growth are dependent on multiple factors, such as balanced 
nutrition, hormonal influences, and physical activity (24,158). 
2.5.2  Risk factors for low bone mineral density  
Race, sex, and ethnicity affect BMD. Individuals of Caucasian origin have lower BMD than 
blacks, already seen in childhood and adolescence (158,162,163). Females have lower BMD 
than males since adolescence, when adjusted with pubertal state (162). Late onset of 
puberty is an independent risk factor for low BMD (164). 
The main nutritional variables affecting BMD are calcium and vitamin D. The 
American Academy of Pediatrics (AAP) guidelines recommended a daily dose of 10 µg 
vitamin D (165), and the Finnish national guidelines recommend 10 µg supplementation 
for children less than 2 years of age and 7.5 µg for children more than 2 years of age (166). 
New studies have shown that a low vitamin D level is more detrimental to Caucasians 
than blacks (163). The recommended daily calcium intake is 800–1,500 mg. An increase in 
the intake of milk and other dairy products is beneficial to bone mineralisation during 
childhood (167). 
BMD is dependent also on physical activity (158,159,168). It has been 
estimated that an active lifestyle can be responsible for up to 17% of the BMD variation 
(159). How physical activity affects BMD is dependent on age and sex (161). 
The impact of overweight on BMD has been controversial in previous studies. 
A recent study found an overweight-related decrease of cortical BMD in adult males, and 
an increase of trabecular BMD in adult females, who had overweight in adolescence (169). 
In another study, a reduced bone size was associated with high fat mass in 8-18 years old 
children (170). Two previous studies have reported negative results between overweight 
and BMD in children and adolescents when adjusted with fat mass, lean mass, and/or 
body weight (171,172). In a Finnish study, normal body fat content was beneficial to bone 
health during growth, whereas both obese and low-weight children and adolescents had 
lower BMD (173). Obese and overweight children and adolescents are prone to have 
fractures compared with normal-weight controls, though the mechanism is unknown and 
likely multifactorial (173,174). There is a remarkable tracking in BMD; children who have 
low BMD are also more likely to have low BMD in adulthood if effective interventions are 
not performed (175). 
Chronic underlying illnesses including different neuromuscular disorders, 
endocrine diseases, gastrointestinal diseases, cystic fibrosis, juvenile arthritis and 
iatrogenic factors like corticosteroids and cancer treatments as well as a history of earlier 
fractures are significant risk factors for decreased BMD (24,176). 
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2.5.3 Bone mineral density measurements and low bone mineral density in childhood 
and adolescence 
Bone is a composite tissue; it includes organic collagen and inorganic minerals forming a 
bone matrix and non-bone tissue (176). Trabecular and cortical bone are arranged 
differently depending on both the composition and geometrical structure. When 
measuring BMD, it is important to consider the bone’s tissue type, mass, and volume 
(176). During growth, the proportions of trabecular and cortical bone vary, and therefore, 
the total BMD is usually used to measure BMD changes during childhood (176). The 
difference between bone growth and actual BMD accretion needs attention when 
measuring BMD in children. In areal BMD (BMDareal), BMD increases when the bone size 
grows, though volumetric BMD (BMDvol) remains the same (176). BMDareal is highly 
dependent on the bone size and height of the child, and thus, BMD is underestimated in 
children of short stature (177,178). Therefore, mathematical models have been developed 
to estimate apparent volumetric BMD (aBMDvol) (179,180). 
DXA is the most common method for measuring BMD in children and adults. 
The common sites are whole body, lumbar spine and femoral neck. DXA measures two-
dimensional BMDareal (g/cm2). Quantitative ultrasound (QUS) is easy to use for peripheral 
bone sites like calcaneus or tibia, and no radiation is needed for measuring. However, both 
bone size and cortical thickness affect the results; this is the limitation of the method (176). 
pQCT allows the measurement of BMDvol (g/cm3) in radius or tibia and the evaluation of 
cortical and trabecular bone separately, and, in addition, the approximation of bone 
strength (176,181). The radiation dose in both DXA and pQCT is low, and it is acceptable 
to use these methods for evaluating growth and development of bone in growing children 
(22). In pQCT examinations, the radiation is < 3 µSv per scanning (182). The natural 
background radiation in Finland is 0.04–0.30 µSv/h (183). 
The International Society for Clinical Densitometry (ISCD) has published 
recommendations for paediatric bone density measured by DXA (184). Age-, gender-, and 
height-specific reference values should be used and presented as z-scores. Instead of 
osteopenia or osteoporosis, the term “low bone mass for chronologic age” is 
recommended to be used when the BMD z-score is less than −2.0 SD (184). The 
osteoporosis diagnosis should be based on a clinically significant fracture history and a 
low BMD in DXA measurement (177,184). The threshold for an increased fracture risk in 
children is not known (24,177). 
2.6 INHALED CORTICOSTEROIDS, SIDE EFFECTS AND BONE 
HEALTH IN CHILDREN 
ICS are the drug of choice for an anti-inflammatory therapy of asthma. Beclomethasone 
dipropionate, budesonide, fluticasone propionate, and triamcinolone are in clinical use in 
Finland. ICS have different efficacy and safety profiles (185). Altogether, absorption from 
the lungs, absorption of swallowed ICS, and first-pass inactivation influence the level of 
corticosteroids in systemic circulation and systemic side effects (185). 
Systemic corticosteroids have severe side effects on bone metabolism, 
mineralisation, and growth (185). Direct effects on bone tissue consist of the suppression of 
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osteoblast activity and the promotion of osteoclast activity, and indirect effects are due to 
secondary hypogonadism, secondary hyperparathyroidism, and decreased secretion of 
adrenal androgens (185). Corticosteroids cause a decrease in both cortical and trabecular 
BMD (186). ICS have less side effects than systemic corticosteroids, and the benefits of ICS 
in the treatment of asthma are undeniable (15,17). The main concerns when ICS have been 
used for a long time are the potential harmful effects on children’s growth and BMD. 
2.6.1 Inhaled corticosteroids and bone mineral density studies 
Short-term observational studies 
Most of the studies evaluating the association between ICS therapy and BMD in children 
and adolescents have been cross-sectional or short-term longitudinal studies. The studies 
have not been able to reveal any association between ICS use and BMD or bone 
biomarkers (187-195). In these studies, BMDareal has been measured by DXA in the lumbar 
spine region. 
The most recent study examined 230 asthmatic pre-pubertal children and 170 
controls at the median age of 8.9 years (196). Participants had used fluticasone propionate 
for at least 5 years with a 200 µg mean daily dose, and controls were newly diagnosed 
asthma patients with no history of ICS medication. BMD was measured from the lumbar 
spine with DXA, and z-scores were compared between cases and controls. There were no 
significant differences between the groups in BMD or in cortisol and osteocalcin levels 
measured at the same time (196). 
Density-related ultrasound was applied in one study (187). Some tendency to 
reduced BMD was observed in 173 asthmatic children, among whom 56% used ICS. The 
medium daily dose as fluticasone equivalents was 286 µg for 6 months, and in this group, 
there were significantly more children with reduced BMD. As expected, consumed ICS 
doses were dependent on asthma severity, and higher physical activity was associated 
with better asthma control (187). 
High-dose observational studies 
The use of ICS with high doses was evaluated in two studies (197,198). In a cross-sectional 
study, 49 asthmatic children aged 5–19 years who were treated with a daily dose of > 1,000 
µg inhaled fluticasone propionate were compared with 32 healthy controls. There were no 
significant differences in biochemical markers or in sex-specific, age-related, bone age-
corrected BMD, measured from the total body and from the lumbar spine (197). In 
contrast, a study of 76 pre-pubertal asthmatic children receiving budesonide propionate > 
800 µg and, in addition, periodical oral corticosteroids had lower weight-adjusted BMD in 
the lumbar spine compared with children receiving 400–800 µg of budesonide propionate 
or no ICS at all (198). Weight was an independent predictor of BMD in multivariate 
analysis (198). 
Long-term observational studies 
Long-term studies have not revealed significant changes in BMD in children treated with 
ICS (18,19,63). 
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In the longest follow-up of children with asthma thus far, the CAMP study, 
the cumulative ICS dose was associated with decreased bone mineral accretion, seen only 
in boys, in 7 years’ follow-up time (18). Oral corticosteroids were allowed when necessary, 
and their use produced a dose-dependent reduction in bone mineral accretion, again seen 
only in boys (18). 
In a Danish study, 157 asthmatic children receiving inhaled budesonide and 
111 without ICS medication were followed up for 3–6 years. The total body BMD was 
measured by DXA, and no significant differences were observed in BMD, bone mineral 
content, total body calcium, or body composition between the groups (19). 
The dependence between height and BMD needs special attention in long-
term follow-up studies, in which the measured BMDareal could increase when the bone 
grows without any increase in BMDvol (24). 
Randomised and controlled trials 
Three randomised and controlled studies were done to test the ICS effect on BMD 
(20,63,199,200). In the French study, 174 children aged 6 to 14 years with persistent asthma 
were randomised to receive 200 µg of inhaled fluticasone propionate or 8 mg of 
nedocromil sodium daily. BMD was measured by DXA in the lumbar spine and the 
femoral neck at baseline, and 12 and 24 months later, and no significant differences were 
found between the groups (63). 
The Finnish randomised, controlled, double-blind study included 136 children 
aged 5–10 years with recently diagnosed asthma (20). Two study groups received 200 µg 
of budesonide daily for 18 months or 200 µg of periodical budesonide daily when needed 
based on symptoms, and the control group received disodium cromoglycate daily for 18 
months. BMD in the lumbar spine was measured by DXA before and after intervention. 
Daily treatment, but not periodical treatment, with budesonide diminished both BMD and 
height velocity compared with the group treated with daily disodium cromoglycate. 
However, the findings change to insignificant when adjusted with height. Authors 
concluded that changes in BMD interacting with changes in height suggest that a follow-
up of children´s height might give an approximation of ICS effects on bone (20). 
In a 15 years old randomised, controlled, double-blind trial, 23 children 
diagnosed with asthma, but without history of recurrent ICS medication, were allocated to 
receive 200 µg of fluticasone propionate and 400 µg of beclomethasone per day and were 
followed up for 20 months (199). DXA was performed at the baseline, and at the end of the 
study, and no significant difference in BMD between groups was found (199). The clear 
shortcoming of the study was the lack of control group with no ICS therapy; in addition, 
confounding factors were not included in the analysis (199). 
2.6.2 Inhaled corticosteroids and fractures 
ICS consumption can impair on BMD, but BMD is not parallel to fracture risk in childhood 
(201). Asthma is associated with an increased risk for injuries (202,203), and ICS use and 
bronchodilator therapies both have been associated with an increased fracture risk in 
children (201). Maybe, asthma itself, not inhaled medication to asthma, is the main factor for 
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increased fracture risk. The asthmatic children may have alterations in cortical bone geometry, not 
related to therapy, but seem to be related to an increased fracture risk (204). 
2.6.3 Inhaled corticosteroids´ effect on growth 
Glucocorticoids inhibit growth due to the decrease in growth hormone secretion, insulin-
like growth hormone secretion, and direct inhibition of collagen synthesis (205). The use of 
ICS has been associated with temporary growth retardation in childhood, however with 
no significant effect on height in adulthood (17,206,207). This was confirmed in a recent 
review (208). Although the CAMP study reported a 1.2 cm decrease in adult height in 
children who used ISC during childhood, the decrease was seen after 2 years’ treatment, 
and it was not progressive or cumulative (16). There is preliminary evidence of the 
benefits of a new ICS, ciclesonide, which has resulted in less growth reduction than other 
ICS during the first years of treatment (208). 
2.6.4 Other side effects of inhaled corticosteroids 
The potential side effects of corticosteroids include adrenal insufficiency and 
hypothalamus-pituitary axis insufficiency, but the risk of hypoglycaemia is small if ICS are 
used with conventional doses (209,210). The risk increases if a high dose of ICS, especially 
fluticasone propionate, is used for a long time aside with topical and intranasal steroids 
(209). Patients using ICS have a dose-dependent risk of skin thinning and bruises as well 
as a risk of a cataract in adults (17). Available data does not show an increased risk to these 
less common side effects in children if low or moderate doses are used (210). 
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increased fracture risk. The asthmatic children may have alterations in cortical bone geometry, not 
related to therapy, but seem to be related to an increased fracture risk (204). 
2.6.3 Inhaled corticosteroids´ effect on growth 
Glucocorticoids inhibit growth due to the decrease in growth hormone secretion, insulin-
like growth hormone secretion, and direct inhibition of collagen synthesis (205). The use of 
ICS has been associated with temporary growth retardation in childhood, however with 
no significant effect on height in adulthood (17,206,207). This was confirmed in a recent 
review (208). Although the CAMP study reported a 1.2 cm decrease in adult height in 
children who used ISC during childhood, the decrease was seen after 2 years’ treatment, 
and it was not progressive or cumulative (16). There is preliminary evidence of the 
benefits of a new ICS, ciclesonide, which has resulted in less growth reduction than other 
ICS during the first years of treatment (208). 
2.6.4 Other side effects of inhaled corticosteroids 
The potential side effects of corticosteroids include adrenal insufficiency and 
hypothalamus-pituitary axis insufficiency, but the risk of hypoglycaemia is small if ICS are 
used with conventional doses (209,210). The risk increases if a high dose of ICS, especially 
fluticasone propionate, is used for a long time aside with topical and intranasal steroids 
(209). Patients using ICS have a dose-dependent risk of skin thinning and bruises as well 
as a risk of a cataract in adults (17). Available data does not show an increased risk to these 
less common side effects in children if low or moderate doses are used (210). 
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3 Aims of the Study 
The principal aims of the present post-early-life wheezing study were to evaluate the 
association between weight status and asthma, allergy, and lung function at school age 
and to explore the association between the use of ICS during childhood and BMD assessed 
at later school age in children who suffered from severe wheezing in infancy. 
The specific aims of the study were as follows:  
1. to evaluate the association between weight status and asthma or allergy at
preschool and school age after early childhood wheezing, with a special focus on
the influence of emerging overweight, including the association between weight
status and atopic sensitisation or bronchial reactivity;
2. to explore the association between overweight or obesity and lung function at
school age after early childhood wheezing, with a special focus on the influence of
an emerging overweight;
3. to study the association between the use of ICS during childhood and the BMDareal
during adolescence by DXA in the lumbar spine and femoral neck and to compare
BMDareal measurements and aBMDvol results;
4. to evaluate the association between the use of ICS during childhood and BMDvol
during adolescence by pQCT in the distal tibia and radius.
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4 Subjects and Methods 
4.1 ORIGINAL STUDY DESIGN, ENROLMENT OF THE PATIENTS, AND 
BACKGROUND DATA 
One hundred consecutive children hospitalised for respiratory-infection-associated 
wheezing at the age of 1–23 months were recruited into this follow-up study in 1992–1993 
(211). Exclusion criteria were maintenance therapy for asthma, presence of a chronic 
cardiopulmonary disease or respiratory failure in admission. The wheezing episode was 
the first one in 87% of the included children (211). 
Background data were collected by interviewing the parents during 
hospitalisation using a structured questionnaire, which included history of wheezing and 
AD, family history of asthma and other atopic diseases, information on maternal smoking 
during pregnancy, later exposure to tobacco smoke, and pets at home and day care 
attendance (212). Seven respiratory viruses, including RSV, were studied using antigen 
and antibody assays (213). 
The aims of the primary study were to evaluate the acute-phase treatment of 
bronchiolitis and to start the prospective follow-up study to explore the impact of an 
early-life intervention with anti-inflammatory medicines, including ICS (212), and to 
reveal risk factors for asthma after early-life wheezing (213). 
4.1.1 The early childhood intervention protocol 
After hospitalisation, children were randomised into three intervention groups; 34 were 
treated with inhaled budesonide 1,000 µg per day for 8 weeks and then 500 µg per day for 
a further 8 weeks, and 34 were treated for 8 weeks with 80 mg of sodium cromoglycate per 
day and then 60 mg per day for a further 8 weeks (212). The control group consisted of 32 
children who had no anti-inflammatory medication. The follow-up protocol included 
visits at 6 and at 16 weeks and at 8 and 12 months after the beginning of the study (213). 
4.1.2 Virus determination 
Seven viral pathogens were studied in nasopharyngeal aspirates (NPA) and paired sera, 
including both antigen and antibody tests for RSV (213). Later, frozen NPA samples were 
studied by polymerase chain reaction for RSV and rhinoviruses (214,215). In all, RSV was 
identified in 29 of 100 cases and rhinovirus in 27 of 81 cases (216). 
4.2 FOLLOW-UP VISITS DURING CHILDHOOD 
Three follow-up visits were prospectively organised after the intervention (Figure 2). 
Three years after the index wheezing, 83 children attended the preschool-age visit at 4.0 
years of median age (217). Six years after the index wheezing, 82 children attended the 
early school-age visit at 6.3 years of median age (218). The third follow-up visit was 
arranged 11 years after the index wheezing, and 81 of 100 children attended the later 
school-age visit at 12.3 years of median age (50). 
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Figure 2. Control visits, numbers of children attending the visits and the forming of study 
groups of the present study. 
4.2.1 Medical examination and anthropometric measurements 
A research doctor performed the medical examination at all follow-up visits (50,213,216,218). 
During each visit, an experienced nurse measured weight and height using a stadiometer 
and a calibrated weight scale. At the late school-age visit, a pubertal stage was examined 
and recorded (50,219,220). Parents and children were interviewed using a structured 
questionnaire and asthma and allergic symptoms during the preceding 12 months were 
recorded. Ongoing asthma medication was registered, and the use of ICS between follow-
up visits was noted (50). 
4.2.2 Definition of asthma and asthma prevalence at follow-up visits 
At the preschool-age follow-up visit at 4.0 years of median age, 45 (51%) of 89 children 
were considered having asthma. The criteria for asthma were as follows: the child had 
continuous anti-inflammatory medication for asthma, or the child had suffered from two 
or more doctor-diagnosed wheezing episodes after the index wheezing (217). In the early 
school-age follow-up visit, asthma was present in 33 (40%) of 82 children. The criteria for 
asthma were as follows: the child had continuous inhaled anti-inflammatory medication 
for asthma, or the child had two or more parent-reported, doctor-diagnosed wheezing 
episodes or parent-reported prolonged (> 4 weeks) cough without infection during the 
preceding 12 months and the exercise challenge test (ECT) was pathological (218). At late  
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Control visit at 4.0 years of age 
n=83 
Control visit at 6.2 years of age 
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school-age visit, 32 (40%) of 81 children had asthma with the following criteria: the child 
had continuous or intermittent inhaled anti-inflammatory medication for asthma during 
the preceding 12 months, or the child had two or more parent-reported, doctor-diagnosed 
wheezing episodes or prolonged (> 4 weeks) cough apart from infection during the 
preceding 12 months and the ECT was pathological (50). 
4.2.3 Allergy tests and atopic diseases 
Allergen-specific IgE antibodies were measured at 2000, from frozen samples collected 
during index wheezing (50). At the control visits, doctor-diagnosed AD and AR during the 
preceding 12 months were recorded (50,217,218). Skin prick tests (SPTs) were performed at 
school-age control visits against common indoor and outdoor allergens like pollens and 
animal dander (50,218). The reactions with a mean diameter of at least 3 mm were defined 
to be positive, and no reactions were allowed for negative controls (saline). Atopic 
sensitisation was defined as the presence of at least one positive result in SPTs to indoor or 
outdoor allergens (50,218). 
4.2.4 Risk factors for asthma in this cohort 
In the previous studies from this cohort, predictive factors for asthma at 12.3 years of 
median age were AD and specific IgE sensitisation to inhalant, but not to food allergens as 
group, registered during index wheezing (50). Asthma was more common in children who 
were > 12 months old when hospitalised for wheezing (50). Parental asthma or atopic 
diseases, or exposure to pets or maternal smoking during pregnancy, were not risk factors 
for asthma during adolescence in the adjusted analysis (50). The non-RSV aetiology for 
bronchiolitis was a significant risk factor for later asthma at 7.2 years of median age 
(214,216). 
4.2.5 Lung function measurements and bronchial reactivity 
Lung function was studied using flow-volume spirometry (FVS) (Medikro, Kuopio, 
Finland) at 7.2 and 12.3 years of median age (221,222). The parameters were expressed as 
percentages of the gender-specific height-related reference values (% predicted) for 
Finnish children (222,223). FVC, FEV1/FVC, MEF50, and MEF25 were registered. The 
measurement with the highest FEV1 was recorded for analysis in the early school-age 
study (221). In the later school-age visit, the composite maximal curve for each child was 
recorded (222). The used cut-off limits for abnormal values were 80% for FEV1, 88% for 
FEV1/FVC, 62% for MEF50, and 48% for MEF25 (221,222,224). Lung function data were 
available from 79 children at 7.2 years of median age and from 81 children at 12.3 years of 
median age (221,222). 
BHR was studied at both school-age control visits (221,222). The ECT was 
performed as an 8-minute free outdoor running test, including heart rate monitoring 
(Polar Sport Testes; Polar Electro, Kempele, Finland), and done after baseline FVS. At the 
early school-age visit, FVS was repeated 10 minutes after exercise, and the two FEV1 falls 
of > 12% and > 15% were used as cut-off points for increased bronchial reactivity (221). At 
the late school-age visit, the FVS was repeated 5, 10, and 15 minutes after exercise, and > 
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the late school-age visit, the FVS was repeated 5, 10, and 15 minutes after exercise, and > 
24 
10% fall in FEV1 was regarded as positive BHR (222). In addition, metacholine challenge 
test was performed at 12.3 years of age (222). 
4.3 CURRENT STUDY DESIGN AND DATA 
The data concerning lung function, bronchial reactivity, allergic sensitisation, and asthma 
were collected during the study visits. Data were analysed together with the weight and 
height data from the same study visits to explore the effect of overweight and obesity on 
these parameters. The BMD was measured at the follow-up visit at 12.3 years of age. 
Fourteen children, hospitalised for wheezing during enrolment to the primary study in the 
Kuopio University Hospital, but not willing to attend the intervention trial, were invited 
to the follow-up study visit at 12.3 years of median age. Their background information 
was collected with a questionnaire and by interviewing the parents. Their data were used 
in the BMD study only. The ICS consumption history for all participants was collected, 
with the parents' written consent, from the hospital and primary health care medical 
records. 
4.3.1 Definition of obesity 
For the evaluation of the weight status, the body mass index (BMI) was calculated by 
using the following equation: weight (kg) / [height (m2)]. BMI standard deviation scores 
(BMI-SDS), also called z-scores, were calculated by using the freely available obesity 
calculator (225). This calculator applies British age- and sex-specific growth references 
from 1990, produced by the LMS method in 1995 (226,227) and revised in 1996 (228). The 
LMS method summarises the distribution of BMI at each age by its median (M), coefficient 
of variation (S), and skewness expressed as a Box-Cox power (L) required to transform the 
data to normal (229). 
The International Obesity Task Force workshop for childhood obesity 
evaluation recommends the use of BMD > 91st percentile as a cut-off point for overweight 
and > 98th percentile for obesity, corresponding to BMIs > 25 and > 30 kg/m2, respectively, 
in 18-year-old young adults (67). In this study, we used the corresponding BMI-SDS cut-
off points: BMI-SDS > 1.3 for overweight and BMI-SDS > 2.0 for obesity (7,67). 
The Finnish national growth charts, presenting weight for height, are used to 
evaluate the weight in clinical practice (230). In weight for height, the cut-off point for 
overweight and obesity varies depending age, and the method is not in international use. 
Finnish sex-specific and age-related BMI references were published in 2011 (231), and thus 
were not available for the present study. 
4.3.2 Data on inhaled corticosteroid medication 
None of the children had asthma or had used ICS before recruitment in the study (213). As 
a part of the early-life intervention, 23 of 84 children had received budesonide for 16 
weeks immediately after hospitalisation (213). Later in childhood, 40%–50% of the children 
had been diagnosed with asthma and 15%–37% were on ICS medication for asthma during 
the follow-up period (50). 
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There was no scheduled protocol for maintenance medication with ICS after 
the 16-week early childhood intervention. Asthma medication was prescribed when 
required, based on the presence of asthma diagnosis, symptoms, and individual clinicians’ 
decisions. The data on ICS consumption during childhood were collected at the later 
school-age visit by charting the hospital and primary health care records and by 
interviewing the parents using structured questionnaires. The durations and daily doses 
of ICS therapy were collected. The dose of fluticasone propionate was multiplied by 2 to 
be equivalent with the doses of budesonide and beclomethasone dipropionate in the 
calculations; with the awareness of the fact the ICS are not equal to each other (185). The 
cumulative doses and the total time of ICS therapy were calculated and also noted 
separately for the two age periods: 0–6 years and 6–12.3 years (median). A continuous or 
intermittent use of ICS for 6 months or longer during the 6-year age period was 
considered as a regular use. 
Oral and parenteral corticosteroid courses were collected and presented as 
cumulative doses and classified with the cut-off points at the 10th, 50th, and 90th 
percentiles. Children who never received ICS formed the control group of the study. 
4.3.3 Bone mineral density measurements 
The BMD was measured at the late school-age visit in the Department of Clinical 
Physiology and Nuclear Medicine, Kuopio University Hospital. BMD was measured by 
two separate methods, DXA and pQCT. BMD was measured in children followed from the 
index wheezing episode onwards, and from those additional 14 children invited to the 
BMD study at the late school-age visit. 
4.3.4 Dual-energy x-ray absorptiometry 
DXA measurements were performed by trained nurses, using the same scanner (Lunar 
Radiation Corp., Madison, WI) for all 89 children. Measurements were obtained from the 
lumbar spine at the L2–L4 level and from the femoral neck region. Quality assurance tests 
using the Lunar DPX scanner have shown an inter-assay variation ranging between 0.08% 
(for lumbar spine) and 2.3% (for femoral neck) in children (232). 
DXA measures the BMDareal (g/cm2), which is dependent on bone size 
(179,233,234). The aBMDvol (g/cm3) was calculated to minimise the effect of bone size on 
the results (179). Femoral neck aBMDvol was calculated according to the following 
equation: aBMDvol = BMD × [(4/π) × (height for measurement area / measurement area for 
femoral neck)]; and lumbar spine aBMDvol was calculated according to the following 
equation: aBMDvol = BMD × [4 / (π × width of measurement area in the lumbar spine) 
(232). Finnish and international reference values are available for both BMDareal and 
aBMDvol, allowing expression of the results in z-scores (232,235). However, there are no 
specific cut-off points for an increased risk of clinical manifestations such as fractures (23). 
We used both BMDareal and aBMDvol as continuous variables without reference-based 
classifications. 
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the follow-up period (50). 
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There was no scheduled protocol for maintenance medication with ICS after 
the 16-week early childhood intervention. Asthma medication was prescribed when 
required, based on the presence of asthma diagnosis, symptoms, and individual clinicians’ 
decisions. The data on ICS consumption during childhood were collected at the later 
school-age visit by charting the hospital and primary health care records and by 
interviewing the parents using structured questionnaires. The durations and daily doses 
of ICS therapy were collected. The dose of fluticasone propionate was multiplied by 2 to 
be equivalent with the doses of budesonide and beclomethasone dipropionate in the 
calculations; with the awareness of the fact the ICS are not equal to each other (185). The 
cumulative doses and the total time of ICS therapy were calculated and also noted 
separately for the two age periods: 0–6 years and 6–12.3 years (median). A continuous or 
intermittent use of ICS for 6 months or longer during the 6-year age period was 
considered as a regular use. 
Oral and parenteral corticosteroid courses were collected and presented as 
cumulative doses and classified with the cut-off points at the 10th, 50th, and 90th 
percentiles. Children who never received ICS formed the control group of the study. 
4.3.3 Bone mineral density measurements 
The BMD was measured at the late school-age visit in the Department of Clinical 
Physiology and Nuclear Medicine, Kuopio University Hospital. BMD was measured by 
two separate methods, DXA and pQCT. BMD was measured in children followed from the 
index wheezing episode onwards, and from those additional 14 children invited to the 
BMD study at the late school-age visit. 
4.3.4 Dual-energy x-ray absorptiometry 
DXA measurements were performed by trained nurses, using the same scanner (Lunar 
Radiation Corp., Madison, WI) for all 89 children. Measurements were obtained from the 
lumbar spine at the L2–L4 level and from the femoral neck region. Quality assurance tests 
using the Lunar DPX scanner have shown an inter-assay variation ranging between 0.08% 
(for lumbar spine) and 2.3% (for femoral neck) in children (232). 
DXA measures the BMDareal (g/cm2), which is dependent on bone size 
(179,233,234). The aBMDvol (g/cm3) was calculated to minimise the effect of bone size on 
the results (179). Femoral neck aBMDvol was calculated according to the following 
equation: aBMDvol = BMD × [(4/π) × (height for measurement area / measurement area for 
femoral neck)]; and lumbar spine aBMDvol was calculated according to the following 
equation: aBMDvol = BMD × [4 / (π × width of measurement area in the lumbar spine) 
(232). Finnish and international reference values are available for both BMDareal and 
aBMDvol, allowing expression of the results in z-scores (232,235). However, there are no 
specific cut-off points for an increased risk of clinical manifestations such as fractures (23). 
We used both BMDareal and aBMDvol as continuous variables without reference-based 
classifications. 
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4.3.5 Peripheral quantitative computed tomography 
pQCT was performed to measure volumetric total BMD, trabecular BMD, and cortical 
BMD (BMDtot, BMDtrab, and BMDcort, respectively) (Stratec XCT 2000; Stratec 
Medizintechnik, Pforzheim, Germany) at the distal radius and distal tibia. Image data 
were analysed using commercial pQCT analysis software (Bonalyse Geanie 2.1, Jyväskylä, 
Finland). Volumetric thresholds were adjusted within the software for the automated 
analysis to match the current adolescence bone density values. After the completion of 
autoanalysis, results were visually verified by the researcher (Toni Rikkonen, Ph.D.). BMD 
and cortical thickness were measured at the distal radius (4% site) and distal tibia 
measurements from the medial malleolus to the medial condyle (33% site). There are no 
Finnish reference values for pQCT for children available, neither are there specific cut-off 
points for an increased risk of clinical manifestations (23). Therefore, we analysed the 
BMD as continuous variables without reference-based classifications. 
4.4 ETHICS 
The study was approved by the Research Ethics Committee of Kuopio University and 
Kuopio University Hospital. Informed written consent was obtained from the parents of 
the children. The methods used in the study, like blood tests, lung function tests, and BMD 
measurement with DXA, are routinely used in pediatric clinical practice. Only pQCT is a 
new method not routinely used, but the level of radiation is low, and concerns only 
peripheral parts of the body, that is radius and tibia in the present study. Both DXA and 
pQCT are internationally accepted methods to the measurement of BMD in children for 
research purposes. 
4.5 STATISTICS 
In the analysis between asthma, allergy, and weight status, logistic regression was used for 
both univariate and multivariate analyses. The results were expressed as crude odds ratio 
(cOD) and adjusted odds ratio (aOD) with 95% confidence intervals (95% CI). The analysis 
for an association between weight status and asthma or BHR was adjusted for AD in the 
infancy and RSV aetiology of wheezing. The analysis for an association between weight 
status and allergy or atopic sensitization was adjusted for sex and RSV aetiology of 
wheezing. The presence of AD in infancy had a strong interaction with later allergy and 
atopic sensitization; therefore, AD was not included in the analyses. The age on admission, 
although interacting with the viral aetiology of bronchiolitis, was included in all analyses 
as a continuous variable. 
In the analysis of lung function data, the Mann–Whitney U-test was used in 
univariate analyses and the analysis of variance (ANOVA) was used in multivariate 
analyses for continuous FVS parameters. The ANOVA analyses were adjusted for the RSV 
aetiology of index wheezing, in addition to adjustment with anti-inflammatory asthma 
medication during the preceding 12 months before the study visit. Logistic regression 
analysis, adjusted for the RSV aetiology of index wheezing and anti-inflammatory asthma 
medication during the 12 preceding months before the study visit, was applied for 
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categorised (by the limits of abnormal values in % predicted) FVS parameters, and the 
results were expressed as aOR with 95% CI. Sex and age were not included in ANOVA or 
logistic regression, while the FVS references were age and sex specific. 
In the BMD study, Student’s t-test was used for continuous variables in 
univariate analyses and ANOVA in multivariate analyses for the BMD measured by DXA. 
The analysis was adjusted for age, sex, weight as BMI-SDS (normal, overweight, and 
obesity), and the pubertal stage (pre-puberty and early puberty vs. puberty), and use of 
systemic corticosteroids (10th, 50th, and 90th percentiles). Height was also included in the 
model when BMDareal was the outcome. The results are expressed as means with 95% CI. 
Pearson’s correlation coefficients (r, r2) were used for estimating correlations. 
Student’s t-test was used to analyse pQCT data for continuous variables in the 
univariate analyses and ANOVA in multivariate analyses. Multivariate analysis was 
adjusted for age, sex, weight as BMI-SDS (normal, overweight, obesity) and the pubertal 
stage (prepuberty and early puberty vs. puberty), and use of systemic corticosteroids 
(10th, 50th, and 90th percentiles). The results are expressed as means with 95% CI. 
Pearson’s correlation coefficients (r, r2) were used for estimating correlations 
Data were analysed using SPSS version 17 for weight study data and DXA data and 
SPSS version 19 for pQCT data (SPSS Inc., Chicago, IL). 
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Table 2. Asthma and allergic diseases at early and late school age in children after early 
childhood wheezing: an association with overweight 
Asthma or 
allergic 
diseases at the 
school-age 
control visits 
Overweight at 
7.2 years of 
age1
aOR
(95% CI)2
Overweight at 
12.3 years of 
age1 
aOR
(95% CI)2 
Yes 
n = 19 
No 
n = 63 
Yes 
n = 27 
No 
n = 54 
Asthma 
n = 33/31 8 25 
1.14
(0.35–3.65) 12 19 
2.05 
(0.70–6.00) 
Bronchial 
hyperreactivity3 
n = 13/17 
4 9 1.41 (0.36–5.51) 7 10 
1.76 
(0.51–6.07) 
Atopic dermatitis 
n = 26 9 33 
0.83
(0.29–2.37) 8 18 
0.87 
(0.30–2.50) 
Allergic rhinitis 
n = 33/27 6 27 
0.46 
(0.15–1.47) 10 17 
1.18 
(0.43–3.25) 
Atopic 
sensitisation4 
n = 38/50 
11 27 1.32 (0.42–4.18) 14 36 
0.53 
(0.20–1.45) 
1 BMI-SDS > 1.3. 
2 Odds ratio (aOR), and 95% confidence interval (95%CI) by logistic regression: Asthma and 
BHR were adjusted for age, atopic dermatitis in infancy, and RSV aetiology of bronchiolitis; AD, 
AR and AS were adjusted for age, sex, and RSV aetiology of bronchiolitis. 
3 FEV1 decrease > 12% in the exercise challenge. 
4 At least one positive reaction in SPTs. 
Sensitisations to indoor and outdoor allergens were analysed separately at the 
late school-age visit, and previous sensitisation at 7.3 years of age was added to the 
adjusted model. Current overweight and obesity at the late school-age visit were 
associated with a decreased risk for sensitisation to outdoor allergens; aOR = 0.10, 95% CI 
= 0.02–0.52 for overweight and aOR = 0.03, 95% CI = 0.00–0.27 for obesity. 
The previous overweight at 7.2 years of median age was not associated with 
asthma, BHR, AD, AR, or atopic sensitisation at 12.3 years of median age (Table 3), 
corresponding association were non-significant also for obesity (I/Table 3). 
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Table 3. Asthma and allergic diseases at late school age and overweight at early school age in 
children after early childhood wheezing: an association with overweight 
Asthma or allergic diseases 
at the late school-age 
control visit 
Overweight at 7.2 years of age1 
Yes n=16 No n=58 aOR4 (95% CI)2 
Asthma n=28 7 21 1.98 (0.56-7.07) 
Bronchial hyperreactivity2 n=17 3 14 0.73 (0.16-3.26) 
Atopic dermatitis n=24 3 21 0.87 (0.30-2.50) 
Allergic rhinitis n=24 4 20 1.18 (0.43-3.25) 
Atopic sensitisation3 n=45 8 37 0.53 (0.20-1.45) 
1 Overweight BMI-SDS >1.3; b Obesity BMI-SDS >2 (Body mass index standard 
deviation score = Z-score) 
2FEV1 decrease >12% in the exercise challenge 
3At least one positive reaction: 36 to indoor and 38 to outdoor allergens. 
4Odds ratio (aOR), and 95% confidence interval (95%CI) by logistic regression: asthma and 
BHR adjusted for age, atopic dermatitis in infancy and RSV aetiology of bronchiolitis; AD, AR 
and AS adjusted for age, gender and RSV aetiology of bronchiolitis. 
5.3 INFLUENCE OF OVERWEIGHT ON LUNG FUNCTION AT SCHOOL AGE 
5.3.1 Univariate analyses 
At the early school-age visit, current overweight was associated significantly with lower 
FEV1/FVC (Table 4). There were no significant associations between other FVS parameters 
and overweight (Table 4) or obesity (II/Table 1). Previous overweight (Table 5) at the 
preschool-age control visit had no significant association with any FVS parameters at 7.2 
years of median age. There was not possibility to evaluate effect of previous obesity 
because low incidence of obesity. 
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Table 4. Flow-volume spirometry at 7.2 years of median age in relation to current overweight 
Parameters in 
FVS2 
Current overweight1
Yes 
(N=16) 
Mean, (SD) 
No 
(N=58) 
Mean, (SD) 
Univariate 
p3 
Multivariate
p4
FVC 108.71 (19.75) 102.06 (16.48) 0.252 0.219 
FEV1 100.16 (14.16) 99.95 (13.94) 0.977 0.890 
FEV1/FVC 92.63 (8.95) 98.47 (8.93) 0.017 0.025 
MEF50 84.00 (17.73) 85.10 (20.39) 0.700 0.814 
MEF25 66.00 (19.85) 71.27 (22.76) 0.394 0.454 
1 Overweight BMI-SDS >1.3  
2 FVC (forced vital capacity), FEV1 (forced expiratory volume in one second), FEV1/FCV, MEF50
(maximal expiratory flow at 50% of FVC) and MEF25 (maximal expiratory flow at 25% of FVC), 
expressed as % of predicted. 
3 Mann-Whitney U -test 
4 Analysis of variance, adjusted for RSV aetiology of early wheezing and current anti-
inflammatory asthma medication (during the preceding 12 months). 
Table 5. Flow volume spirometry at 7.2 years of median age and association to weight at the 
preschool-age 
FVS at 7.2 years 
of age 
Weight at 4.0 years of age 
Overweight1 
n = 5 p
2 Normal weight 
n = 67 
FVC 107.95 (8.8) NS 102.91 (8.47) 
FEV1 98.39 (13.27) NS 99.81 (14.52) 
FEV% 90.99 (9.53) NS 97.64 (9.41) 
MEF50 79.44 (23.23) NS 85.56 (19.72) 
MEF25 59.43 (21.44) NS 71.15 (23.06) 
Data are presented as mean (SD). FVC, forced vital capacity; FEV1, forced expiratory volume 
in 1 sec; FEV1/FCV and MEF50, maximal expiratory flow at 50% of FVC; MEF25, maximal 
expiratory flow at 25% of FVC, expressed as % predicted. 
1 Overweight BMI-SDS > 1.3. 
2 Mann-Whitney U-test and ANOVA, adjusted for the RSV aetiology of early wheezing and 
current anti-inflammatory asthma medication. 
There was no significant association between FVC or FEV1 and overweight or 
obesity at school-age visits (Table 4 and II/Tables 2 and 3). Previous overweight and 
obesity at 7.2 years of median age associated significantly with lower FEV1/FVC at 12.3 
years of median age (Table 6). Current overweight and obesity associated significantly 
with lower FEV1/FVC, MEF50% (Table 6) and with MEF25 (p 0.006 and p 0.021 
respectively) at late school age (II/Tables 2 and 3). 
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5.3.2 Multivariate analyses 
In the multivariate analysis at the early school-age visit, both overweight and obesity 
associated significantly with decreased FEV1/FVC (Table 4 and II/Table 1). At the later 
school-age visit, the association of current overweight with FEV1/FVC and MEF25% 
remained as significant after adjusting with RSV aetiology of index wheezing and current 
anti-inflammatory asthma medication, but the association with MEF50 became non-
significant (Table 6 and II/Tables 2 and 3). 
5.3.3 Logistic regression 
Previous and current overweight were significant risk factors for decreased FEV1/FVC (< 
88% of predicted) at the early school-age (Table 7) and late school-age visits (Table 8). At 
late school age, current obesity was also a significant risk factor for abnormal FEV1/FVC (< 
88%) (aOR = 8.07, 95% CI = 2.10–31.05) and MEF25 (< 48%) (aOR = 4.34, 95% CI = 1.06–
17.79). The weight did not associate to decreased FEV1 (Table 7 and 8). 
 Because overweight was highly persistent between the study visits, previous 
and current overweight could not be incorporated in the same multivariate model. 
Therefore, it was not reliable to evaluate causality and influences separately. 
Table 7. Logistic regression: abnormal lung function in FVS at the early school-age visit, in 
relation to previous and current overweight 
Abnormal 
FVS2 
7.2 years of age 
Previous 
overweight1,4 aOR (95% CI)3 
Current 
overweight1,5 aOR (95% CI)3 Yes  
n = 5 
No  
n = 69 
Yes  
n = 17 
No  
n = 57 
FEV <80% - 4 - 1 3 1.01 (0.10–10.58) 
FEV1/FVC 
< 88% 3 10 
15.46  
(1.65–145.26) 6 7 3.71 (1.01–13.60) 
MEF50 < 
62% 2 11 6.46 (0.77–33.95) 3 11 0.89 (0.21–3.80) 
1 BMI-SDS > 1.3. 
2 FEV1/FCV and MEF50, maximal expiratory flow at 50% of FVC, expressed as % predicted. 
3 Odds ratio (95% CI) adjusted for RSV aetiology of early wheezing and current anti-
inflammatory asthma medication (during the preceding 12 months). 
4 Overweight at 4.0 years of median age. 
5 Overweight at 7.2 years of median age. 
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Table 8. Logistic regression: abnormal lung function in FVS at the late school-age visit, in 
relation to previous and current overweight 
 12.3 years of median age 
Abnormal 
FVS2 
Previous 
overweight1,4 aOR (95% CI)3 
Current 
overweight1,5 aOR (95% CI)3 
 Yes  
n = 16 
No  
n = 58 
Yes  
n = 24 
No  
n = 50 
FEV1 
<80% 2 10 
0.70 
(0.13–3.60) 5 9 
1.00 
(0.29–3.46) 
FEV1/FVC 
< 88% 6 6 
5.64 
(1.43–22.20) 8 5 
4.02 
(1.14–14.22) 
MEF50 < 
62% 3 9 
1.29 
(0.30–5.54) 7 6 
2.64 
(0.78–8.97) 
1 BMI-SDS > 1.3. 
2 FEV1/FCV and MEF50, maximal expiratory flow at 50% of FVC, expressed as % predicted. 
3 Odds ratio (95% CI) adjusted for RSV aetiology of early wheezing and current anti-
inflammatory asthma medication (during the preceding 12 months). 
4 Overweight at 7.2 years of median age. 
5 Overweight at 12.3 years of median age. 
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5.4 BONE MINERAL DENSITY BY DUAL-ENERGY X-RAY 
ABSORPTIOMETRY 
BMDareal was measured and aBMDvol was calculated for 65 boys and 24 girls by DXA. 
Among these 89 children, 37% were overweight and 24% were obese, and 28% of boys and 
38% of girls were at puberty (M/G3-5). Pubertal children had higher BMDareal and aBMDvol 
in the lumbar spine and higher BMDareal in the femoral neck compared with prepubertal 
children (Table 9). In the lumbar spine, BMDareal and aBMDvol were lower in boys than in 
girls (Table 9). Overweight or obesity had no significant association with BMDareal or 
aBMDvol in the lumbar spine or femoral neck (Table 9). 
Table 9. The association between BMDs measured by DXA and gender, pubertal stage, and 
weight at 12.3 years of age in 89 children hospitalised for wheezing in early childhood 
  BMDareal 
mean (95% CI)1 
aBMDvol 
mean (95% CI)2 
 n Lumbar spine L2–L4 Femoral neck 
Lumbar 
spine L2–L4 Femoral neck 
Female 24 0.95 (0.88–1.02)* 
0.91 
(0.84–0.98) 
0.33 
(0.31–0.35)* 
0.41 
(0.39–0.44) 
Male 65 0.83 (0.80–0.85) 
0.91 
(0.89–0.94) 
0.29 
(0.28–0.30) 
0.39 
(0.38–0.41) 
Pre- and early 
pubertal3 64 
0.82 
(0.80–0.85)* 
0.88 
(0.86–0.91)* 
0.29 
(0.28–0.30)* 
0.40 
(0.38–0.41) 
Pubertal3 24 0.97 (0.91–1.03) 
1.00 
(0.95–1.06) 
0.32 
(0.30–0.34) 
0.42 
(0.39–0.44) 
Normal weight4 56 0.85 (0.81–0.88) 
0.89 
(0.86–0.92) 
0.30 
(0.29–0.31) 
0.40 
(0.39–0.41) 
Overweight4 33 0.89 (0.82–0.96) 
0.96 
(0.88–1.04) 
0.30 
(0.29–0.32) 
0.40 
(0.38–0.42) 
1 Areal BMD (g/cm2) measured by DXA. 
2 Apparent volumetric BMD (g/cm3) calculated from DXA measurements. 
3 Tanner stages M1-2 and G1-2 as pre-puberty and early puberty, M3-5 and G3-5 as puberty. 
4 Normal weight BMI-SDS < 1.3 SD, overweight BMI-SDS > 1.3 SD. 
*Two independent-samples t-test, p < 0.05, between males and females or pre-pubertal/early 
pubertal and pubertal children. 
 The mean cumulative dose of systemic corticosteroids during the follow-up 
period was 161 mg (range = 10–1,784 mg, SD = 346, n = 34), showing no correlation with 
lumbar spine BMDareal (r = 0.058, r2 = 0.00) or aBMDvol (r = −0.137, r2 = 0.02), nor with 
femoral neck BMDareal (r = −0.026, r2 = 0.00) and aBMDvol (r = −0.088, r2 = 0.01). When 
analysed as categorised (at the 10th, 50th, and 90th percentiles), there was no significant 
association between systemic corticosteroids use and BMD in the lumbar spine or femoral 
neck. 
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5.4.1  Effect of inhaled corticosteroids on bone mineral density in the lumbar spine 
and femoral neck 
The mean cumulative dose of ICS expressed as budesonide equivalents during the whole 
follow-up period was 517 mg (range = 31–1,813 mg). There was a significant negative 
association between the cumulative ICS dose and the BMDareal (adj. p = 0.000) and aBMDvol 
(adj. p = 0.006) in the femoral neck (Figure 4 and III/Figures 1A and 1B). The analysis of 
variance was adjusted for use of systemic corticosteroids, age, sex, weight status by BMI-SDS and 
pubertal stage, and height in the analysis of areal BMD. However, the correlations were weak: 
for BMDareal, r = −0.32, r2 = 0.10; for aBMDvol, r = −0.28, r2 = 0.08. There was no significant 
association between the cumulative ICS dose and the BMD in the lumbar spine (Figure 4 
and III/Figures 2A and 2B). 
 
Figure 4. The distribution of BMDareal in lumbar spine and femoral neck at 12.3 years of median 
age in relation to the cumulative dose of ICS used during follow-up time. The presence of 
puberty is shown in figures. 
 In the lumbar spine, both BMDareal and aBMDvol were significantly lower in 
those 12 children who were treated with regular ICS medication only at less than 6 years 
of age compared with those 21 children who never received ICS therapy (Table 10). The 
findings were similar after adjusting with age, sex, pubertal stage, weight status, and the 
use of systemic corticosteroids, and in the case of BMDareal with the additional adjustment 
for height. Concerning the femoral neck, such association was found only with aBMDvol 
(p= 0.031) (III/Table 2). Twelve children had used ICS regularly only between 6 and 12.3 
years of age, and there was no significant association with BMD at age 12.3 years (Table 10 
and Figure 5 and III/Table 2). 
r2 = 0.03 
adj. p = 0.076 
r2 = 0.10 
adj. p = 0.000 
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5.4.1  Effect of inhaled corticosteroids on bone mineral density in the lumbar spine 
and femoral neck 
The mean cumulative dose of ICS expressed as budesonide equivalents during the whole 
follow-up period was 517 mg (range = 31–1,813 mg). There was a significant negative 
association between the cumulative ICS dose and the BMDareal (adj. p = 0.000) and aBMDvol 
(adj. p = 0.006) in the femoral neck (Figure 4 and III/Figures 1A and 1B). The analysis of 
variance was adjusted for use of systemic corticosteroids, age, sex, weight status by BMI-SDS and 
pubertal stage, and height in the analysis of areal BMD. However, the correlations were weak: 
for BMDareal, r = −0.32, r2 = 0.10; for aBMDvol, r = −0.28, r2 = 0.08. There was no significant 
association between the cumulative ICS dose and the BMD in the lumbar spine (Figure 4 
and III/Figures 2A and 2B). 
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age in relation to the cumulative dose of ICS used during follow-up time. The presence of 
puberty is shown in figures. 
 In the lumbar spine, both BMDareal and aBMDvol were significantly lower in 
those 12 children who were treated with regular ICS medication only at less than 6 years 
of age compared with those 21 children who never received ICS therapy (Table 10). The 
findings were similar after adjusting with age, sex, pubertal stage, weight status, and the 
use of systemic corticosteroids, and in the case of BMDareal with the additional adjustment 
for height. Concerning the femoral neck, such association was found only with aBMDvol 
(p= 0.031) (III/Table 2). Twelve children had used ICS regularly only between 6 and 12.3 
years of age, and there was no significant association with BMD at age 12.3 years (Table 10 
and Figure 5 and III/Table 2). 
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Figure 5. Areal BMDareal and aBMDvol in the lumbar spine and femoral neck of children who 
newer used ICS and in those who regularly used ICS only before school age or only at school 
age.  
* Adjusted p < 0.05 between children never received ICS and children received ICS regularly 
before school age. 
* 
* 
* 
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5.5 BONE MINERAL DENSITY BY PERIPHERAL QUANTITATIVE 
COMPUTED TOMOGRAPHY 
BMDvol was measured for 62 boys and 20 girls by pQCT. Among these 82 children, 38% 
were overweight and 26% were obese, and 19% of boys and 40% of girls were at puberty 
(M/G3-5). BMDtot and BMDcort were higher in girls than boys in the tibia (Table 11). Pubertal 
children had higher BMDtot and BMDcort in the radius compared with pre-pubertal or early 
pubertal children (Table 11). Age and weight status, as classified by BMI-SDS (normal 
weight, overweight, and obesity), had no correlation with BMD in the radius (radius 
BMDtot, r = 0.247, r2 = 0.06) or tibia (BMDtot. r = 0.073, r2 = 0.01). Systemic corticosteroid use 
had no significant associations with BMD in the radius (BMDtot, r = 0.063, r2 = 0.00) or tibia 
(BMDtot, r = 0.062, r2 = 0.00). 
Table 11. The association between BMDvol (g/cm3) in distal tibia and radius (mean, 95% CI) and 
sex and pubertal stage at the median age of 12.3 years in 81/82 children hospitalized for 
wheezing in infancy 
Bone Mineral Density in Tibia and Radius1 
Mean, (95% CI)2 
 Female N=20 
Male 
N=61/62 
Pre- and 
early 
pubertal3 
N=59/60 
Pubertal 
N=20 
Tibia BMDtot 
383.8 
(360.7-406.9) 
350.8 
(341.2-360.3)* 
356.6 
(346.2-367.1) 
367.4 
(343.5-391.2) 
Tibia BMDcort 
585.00 
(572.2-597.9) 
564.4 
(559.5-569.3)* 
567.8 
(562.2-573.4) 
575.0 
(561.9-588.1) 
Radius BMDtot 
118,1 
(103.6-132.7) 
124.9 
(120.4-129.3) 
119.7 
(114.7-124.7) 
133.8 
(121.7-146.0)* 
Radius BMDtrad 
84.8 
(73.6-96.0) 
92.5 
(88.0-7.0) 
88.3 
(83.4-93.2) 
98.1 
(88.6-107.7) 
Radius BMDcort 
203.3 
(178.2-228.3) 
209.8 
(204.4-215.2) 
202.8 
(196.3-209.3) 
222.5 
(201.2-243.7)* 
1 BMD measured by pQCT 
2 95% confidence interval  
3 Tanner stage M1-2 and G1-2 as pre- and early pubertal, M3-5 and G3-5 pubertal, two boys 
refused pubertal examination 
* Two independent-samples t-test, p < 0.05, between males and females or pre-pubertal/early 
pubertal and pubertal children 
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 The correlation between BMDtot and BMDcort in the radius and tibia was as 
follows: for BMDtot, r = 0.376, r2 = 0.14; and for BMDcort, r = 0.348, r2 = 0.12 (Figure 6). 
 
Figure 6. The correlation between BMDtot and BMDcort in the distal radius and in tibia, r2 = 0.14, 
r2=0.12 respectively. 
5.5.1 The effect of inhaled corticosteroids to the bone mineral density in distal radius 
and tibia measured by peripheral quantitative computed tomography 
The cumulative ICS dose (mean = 537 mg, range = 31–1,813 mg) as budesonide equivalents 
had a significant negative correlation with BMDtot (r = −0.175, r2 = 0.031, adj. p = 0.016), BMDcort (r 
= −0.138, r2 = 0.019, adj. p = 0.016), and BMDtrab (r = −0.155, r2 = 0.022, adj. p = 0.039) in the radius. 
The correlations were weak (figure 7). For associations, the analysis of variance was adjusted for 
use of systemic corticosteroids, age, sex, weight status by BMI-SDS and pubertal stage (Figure 7). 
The correlations were weak. The corresponding correlations were weaker and associations non-
significant for cortical thickness, or for BMDtot and BMDcort in the tibia. 
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Figure 7. The distribution of BMDtot, BMDcort and BMDtrab in radius at 12.3 years of median age in 
relation to the cumulative dose of ICS used during follow-up time. Correlations and association 
in adjusted ANOVA shown in figures. 
 When the regular ICS use was analysed separately for consumption at less than 
6 years of age and between 6 and 12.3 years of age, there were no significant differences in 
BMDtot in the radius or tibia between children who used ICS regularly and children who 
never used ICS (Table 12). Results were non-significant also for BMDcort and BMDtrab in the 
radius and BMDcort in the tibia (Data not shown). 
r2 = 0.031 
adj. p = 0.016 
r2 = 0.019 
adj. p = 0.016 
r2 = 0.022 
adj. p = 0.039 
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Table 12. MBDtot (g/cm3) in radius and tibia at the median age of 12.3 years in children with 
regular ICS use only before 6 years of age or between 6 to 12.3 years of age, compared to 
BMDtot in radius in children who had never used ICS 
Regular ICS use1 
MBDtot in radius 
(mean, 95% CI)2 
p3 
MBDtot in tibia 
(mean, 95% CI)2 
p3 
Only at age 
0-6 years 
N= 
12 
127,50 
(113.58-140.49) ns 
334.58 
(315.39-353.78.90) ns 
Only at age 
6-12.3 years 
N= 
10 
132.70 
(112.83-152.57) ns 
387.60 
(458.41-416.79) ns 
No ICS use 
during the 12.3 
years follow up 
N= 
18 
123.11 
(116.02-130.21)  
357.28 
(336.85-377.70)  
1 Regular use; over 6 month use of ICS during the 6-year age period 
2 95% confidence interval 
3 The analysis of variance adjusted for sex, pubertal stage (Tanner stage M1-2 and G1-2 as pre 
and early pubertal, M3-5 and G3-5 pubertal), age, height (cm) and weight as BMI-SDS (normal, 
overweight, obesity) and used systemic corticosteroids (classified by 10th, 50th and 90th 
percentiles) 
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6 Discussion 
 
6.1 RELATION OF OVERWEIGHT AND ASTHMA, LUNG FUNCTION, AND 
ALLERGY IN CHILDREN  
6.1.1 Asthma  
This prospective follow up study comprised the children who experienced severe wheezing 
in early childhood and were followed longitudinally for 11 years and thus enables to 
inspect the influence of weight developed and ICS consumptions to the outcomes asthma, 
like lung function and BMD. The present study did not find any association between 
asthma and earlier or current obesity or overweight. Reasons may be the rather low 
proportion of overweight (33%) and especially obese (20%) children, although the 
proportions were higher than on average in Finnish children (19.1%–23.6% and 3.2%–4.7%, 
respectively) (80) and the cohort being small. In line with the present study, when 
objectively measured BHR was demanded for the asthma diagnosis, the other studies have 
been negative also (96,118,151). 
In previous studies, most often the asthma symptoms and diagnoses have been asked from 
parents and have been based on subjective observations (11,132,133,148,149) and the 
connection between asthma and obesity is known (5,6,236). 
 In the present study, we did not find connections between BHR and earlier 
weight at 7.2 or current weight at 12.3 years of age, in line with results from another asthma 
study (237). In longitudinal studies, the results have varied. In a 9-month follow-up, obese 
(BMI > 95 %) children had more wheezing, more use of medicines, and more emergency 
room visits, but no association was found with PEF rates monitored at home (149). Another 
study did not find any associations between asthma, AR, AD, or BHR at 10 years of age and 
current or previous weight status (237). In a birth cohort, an earlier persistent and current 
overweight associated with both dyspnoea and BHR at 8 years of age, whereas earlier 
overweight did not predict BHR if weight had normalised (120). 
 The asthma severity might be one factor modifying the asthma-obesity relation. 
In the present study, we did not monitor asthma severity or the sedentary lifestyle, and 
both might affect the results. Poor asthma control could lower the level of physical activity 
and further lead to weight gain. Another notable issue, the possible causality between 
obesity and asthma, was not possible to evaluate in the present study. In a large 
retrospective cohort study, 5- to 17-year-old obese asthmatic children used more β-agonists 
and more oral corticosteroids, with a conclusion that obesity is associated with a risk of 
worse asthma control (101). In the National Longitudinal Survey of Youth (NLSY) with a 
14-year follow-up time, boys had an increased risk of asthma if they became overweight 
(BMI > 85th percentile) at 2–3 years of age or were overweight during the whole follow-up 
time (134). Also, girls who gained weight at school age had an increased risk of asthma in 
another study (137). 
 Age, puberty and sex have a role in the asthma-obesity relation. In the present 
study, we did not evaluate an association between overweight during the index wheezing 
episode at less than 2 years of age and later asthma, mainly because of the small numbers of 
overweight children at that age. In addition, the cohort was too small, not allowing a 
relevant analysis for boys and girls separately. Therefore, age on admission and sex were 
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included as the confounding factors in the adjusted analyses. In literature, one longitudinal 
study, higher weight at 1 year of age was associated with better lung function at 6 and 8 
years of age, but later, overweight changed to be a risk factor (136). In another study, 
obesity reduced lung function without any major symptoms before puberty. During 
adolescence, FEV1% and FEV1/FVC was reduced in obese girls; and in adults, there were 
no differences in lung function between obese and non-obese subjects (125). In the Tucson 
Children´s Respiratory Study, early puberty and obesity were both associated with 
unremitting asthma after puberty (238). In available studies, the results are rather 
conflicting due to sex interactions (119,127,128,131). 
 These inconsistent findings support, that although obesity increases the asthma 
risk at the population level, it might cause more asthmatic symptoms rather than effect the 
asthma prevalence per se. Asthma associated with obesity differs from atopic asthma and 
may even be an own phenotype (4,110,239,240). Obesity decreases responses to asthma 
medication, and weight reduction improves lung function; both can be seen as a 
demonstration of causality in the asthma-obesity relation (Shore, Johnston 2006), but more 
likely, as a sign of obese asthma phenotype characterised by non-atopic airway 
inflammation (4,110). 
 To clarify the complex interaction between weight and asthma, longitudinal 
preferably prospective and stratified studies with multivariate models are needed to 
answer the following questions: Is excessive weight gain an independent significant risk 
factor for asthma? Are there certain risk groups that should obtain special attention? Do 
obese asthmatic children need a different treatment compared with allergic asthmatic 
children? 
6.1.2 Lung function 
The results of the present long-term follow-up study after early childhood wheezing 
showed that overweight was associated significantly with reduced FEV1/FVC at school age 
and with reduced MEF50 and MEF25 at late school age. 
 In healthy children, overweight has had a beneficial effect on lung function 
(8,9), but decreased lung function related to obesity has also been reported (131). However, 
benefits might change during adolescence; lung function seems first to reach a plateau and 
then to decrease among the obese youths (9). Normal weight is probably the most beneficial 
to lung health; also, low weight was associated with significantly lower FEV1 and FVC 
compared with normal weight children (96). 
 Overweight might have a different effect on lung function in asthmatic than in 
non-asthmatic children; approximately 40% of our patients had asthma, and all had 
wheezed in early childhood. In line with the findings of the present study, in the CAMP 
study, an increasing BMI was associated with increasing FEV1 and FVC but decreasing 
FEV1/FVC (144). In the post hoc analysis of the CAMP data, overweight children had 
decreased responses to ICS when assessed with lung function measurements (103). Obesity-
related lower FEV1/FVC has been reported in a birth cohort study (127), lower residual 
volume/TLC ratios in a case-control study (110) and in a cross-sectional study (147). 
 The decrease of MEF50 and MEF25 values in the overweight and obese 
children at the teenage visit indicates that overweight and obesity might narrow the small 
peripheral airways, as described to occur in obese subjects (93). In addition, the decreased 
compliance of either the lungs due to the narrow peripheral airways or the chest wall due 
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to body adiposity may lead to subnormal lung function, including both decreased airway 
flows, which means an obstructive lung function disorder, and decreased lung volumes, 
which means a restrictive lung function disorder (241). 
 In a Danish study on the effect of childhood weight on lung function in 
adulthood, FEV1 and FVC values were reduced in obese men at 27 years of age, but the 
childhood BMI at 7 years of age was positively associated with both FEV1 and FVC (97).  
 The results of the different studies seem confusing, but there might be some 
consistency; mild overweight may be beneficial, but when substantial overweight or 
obesity develops, the effect turns to detrimental. The effect of excessive weight gain on lung 
function may be age dependent, and different multifactorial mechanisms may influence 
children and adults. 
6.1.3 Allergies 
In the present study, excessive weight gain at late school age decreased the occurrence of 
AD and sensitisation to outdoor allergens. There are only a few other follow-up studies 
concerning the relation between weight status and atopic diseases (127,154). Contrary to the 
present study, atopy and IgE levels associated with height and weight in the birth cohort 
study (127), and AD was connected to weight gain (11,154). In the previous studies, AR has 
been less common in obese children (11), and underweight children even had a higher risk 
for atopy in one study (123). 
 The association between allergy and weight may be sex dependent 
(95,96,114,127). In pooled data from seven epidemiological studies, allergy and overweight 
associated in girls (96), in line with the birth cohort studies (127). The present data were too 
small for relevant stratified sex-based analyses on the association between overweight or 
obesity and atopic diseases. 
 The link between weight status and asthma is poorly known. The most 
common presumption is that overweight or obesity reduces the production of 
inflammatory mediators which further modify the development of allergy. However the 
mechanism probably differs from the asthma obesity connection, which seems to be 
stronger in non-atopic individuals (12). 
6.2 THE EFFECT OF INHALED CORTICOSTEROIDS’ ON BONE MINERAL 
DENSITY IN CHILDREN  
6.2.1 Dual x-ray absorptiometry 
The present follow-up study reveals the association between ICS use and reduced BMD 
measured by DXA at 12.3 years of age. The impact of ICS was seen in two separate ways: 
high cumulative ICS doses associated with reduced BMD in the femoral neck, and a 
significant negative effect on BMD in the lumbar spine and in the femoral neck emerged 
when ICSs has been used regularly before 6 years of age. Well-known confounding factors 
such as age, gender, pubertal stage, height, and weight status and the use of systemic 
corticosteroids were included in adjusted analyses with no substantial changes in results. 
Unfortunately, we did not have the exact data of physical activity and dietary habits to add 
in to the model. 
 Previous long-term follow-up studies have not found similar impacts on BMD, 
or findings have only been marginal (18,19,63). In the largest CAMP study with 4–7 years of 
follow-up time, the use of 200 µg of budesonide daily was associated with decreased bone 
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included as the confounding factors in the adjusted analyses. In literature, one longitudinal 
study, higher weight at 1 year of age was associated with better lung function at 6 and 8 
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mineral accretion, and oral corticosteroids produced a dose-dependent reduction in bone 
mineral accretion in the lumbar spine, but only in boys (18). The Danish study did not find 
any significant differences in total BMD, bone mineral content, or total body calcium 
between the ICS and the non-ICS groups during 3–6 years of follow-up time (19). The most 
recent retrospective cross-sectional study did not find significant differences in lumbar 
BMD between pre-pubertal children using intermittent fluticasone with a 200 µg mean 
daily dose for 5 years and newly diagnosed asthmatic children with no history of ICS 
medication (196). 
 Studies with intermediate follow-up times have similar results. Fluticasone use 
for 2 years did not affect BMD accretion in the lumbar spine and femoral neck compared 
with nedocromil sodium (63). In line with the present study, an Australian study reported 
that the ICS therapy for 9–20 months reduced total bone mineral content in pre-pubertal 
children when compared with controls (190), but unfortunately, long-term follow-up 
results are not available. 
 The median cumulative ICS dose was higher in the present study than in the 
three previous studies (20,63,190,196). The high cumulative dose of ICS up to 1,800 mg 
might be one reason for positive results in this study. 
 Bone size influences the BMDareal values; this can be minimised by the 
calculated aBMDvol, which is similar in large and small bones (242). In the present study, 
aBMDvol and BMDareal gave similar results, and BMDareal results were stable when adjusting 
with height. In the Helsinki Early Intervention Childhood Asthma study, daily treatment 
with budesonide reduced BMD compared with daily disodium cromoglycate in the crude 
analysis, but the results changed to negative when adjusted with height (20). The 
researchers discussed, that monitoring height growth is sufficient for BMD monitoring. The 
interaction between height and BMD requires special attention in long-term follow-up 
studies. Bone size growth is not equal with the accretion of bone mineral content during 
growth (24). Thus, if the baseline BMD is low, it could stay low despite height growth (175). 
Therefore, the suggested height monitoring alone (20) may not be sensitive enough to 
estimate all significant changes in BMD in children receiving ICS medication. 
 Two separate findings of the present study might be explainable by bone 
physiology. The lumbar spine consists mainly of trabecular bone that has a rapid turnover, 
and the femoral neck consists mainly of cortical bone that has a slower turnover; therefore, 
lumbar spine is more susceptible to hormonal and metabolic effects (24). The previous 
studies in children have focused on the lumbar spine, thus mainly reflecting the effects on 
trabecular bone (18-20,63), and only one study has also assessed femoral neck (63). In this 
study, high cumulative doses during childhood were associated with changes in the 
femoral neck representing less frequently studied cortical bone. On the other hand, there 
might be a critical period in early childhood for changes in the lumbar spine representing 
trabecular bone.  
 BMD is dependent on age, sex, pubertal stage, and race (162,181). Physical 
activity increases BMD, and overweight could decrease BMD, but the effects seem to be sex 
and age specific (161,169,170). The number of study subjects in the present study was too 
small for sex-specific analyses, but the sex, age and pubertal stage were taken into account 
in the analyses. In addition, we could not evaluate the effects of ICS on growth in height 
because bone age was not studied by radiology. The Tanner classification is not sufficiently 
exact for the estimation of pubertal stage in growth studies. Also, the ICS preparation can 
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affect the results; the swallowed fluticasone propionate has low bioavailability and 
therefore negative results in studies done with it cannot be generalized to concern other 
ICS´s (196). In the present study, children used various drugs, and doses were estimated as 
the budesonide equivalents. 
6.2.2 Peripheral quantitative computed tomography 
To our knowledge, there are no previous paediatric studies on the effect of ICS on BMD 
measured with pQCT. In the present study, the use of ICS for asthma during childhood was 
associated with reduced BMDvol measured by pQCT at the median age of 12.3 years. The 
pQCT results are in accordance with the findings with DXA. Increasing cumulative ICS 
doses associated with decreasing BMDtot, BMDcort and BMDtrab in the distal radius. The 
results were similar after adjusting with potential confounding factors, such as age, sex, 
pubertal stage and weight status, and the use of systemic corticosteroids. There were no 
significant associations with BMD in the tibia. The present study did not find any age-
specific differences in the ICS effect on BMD in pQCT measurements, and we could not 
confirm the finding that pre-schoolers are in the critical age for ICS side effects to BMD, 
which occurs in the DXA study. 
 Another new method, the density-related ultrasound, was applied in one study 
observing a tendency to reduced BMD in the calcaneal bone of children using ICS 
compared with a non-ICS group (187,187). In that study, asthma severity was associated 
with decreased BMD and physical activity with higher BMD; both are well-known 
confounding factors in BMD measurements. However, the ultrasonography is not 
comparable to DXA in diagnostic accuracy (243). 
 In the present study, data on physical activity were not systematically 
collected. Significant findings were in distal radius, whereas BMD in the tibia was not 
affected. Tibia is under substantial physical loading, which could prevent bones from 
detrimental effects of ICS. The benefits of physical activity to BMD and bone development 
are well known (159,161). In the present study, BMD was lower in the radius than that in 
the tibia, in agreement with earlier studies, but the correlation between the tibia and the 
radius BMD was lower than that in other studies (244). 
6.3 METHODOLOGICAL ASPECT 
6.3.1 Study design 
This study was originally planned to evaluate the treatment of young wheezy children and 
to prevent recurrent obstructions, both being common, thus far unresolved issues in 
paediatrics. One hundred children younger than 2 years of age were recruited, most of 
them during their first wheezing episode. Background data were collected during the index 
wheezing episode in hospital, and follow-up data were collected during the prospectively 
scheduled follow-up visits, at 4.0, 7.2 and 12.3 years of median age. Only doctor-diagnosed 
asthma and other diseases were accepted. During this long-term follow-up study, the term 
bronchiolitis was originally used for index wheezing leading to hospitalisation at less than 
24 months of age. Currently, early childhood wheezing is the more proper term for virus-
induced wheezing in this age group, and it is used in the present thesis. 
 Increasing evidence has confirmed the relation between asthma and obesity, 
obtained mostly from epidemiological and birth cohort studies. At least in adults, asthma 
related to obesity is not equal to atopic asthma. This selected data give new information 
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which occurs in the DXA study. 
 Another new method, the density-related ultrasound, was applied in one study 
observing a tendency to reduced BMD in the calcaneal bone of children using ICS 
compared with a non-ICS group (187,187). In that study, asthma severity was associated 
with decreased BMD and physical activity with higher BMD; both are well-known 
confounding factors in BMD measurements. However, the ultrasonography is not 
comparable to DXA in diagnostic accuracy (243). 
 In the present study, data on physical activity were not systematically 
collected. Significant findings were in distal radius, whereas BMD in the tibia was not 
affected. Tibia is under substantial physical loading, which could prevent bones from 
detrimental effects of ICS. The benefits of physical activity to BMD and bone development 
are well known (159,161). In the present study, BMD was lower in the radius than that in 
the tibia, in agreement with earlier studies, but the correlation between the tibia and the 
radius BMD was lower than that in other studies (244). 
6.3 METHODOLOGICAL ASPECT 
6.3.1 Study design 
This study was originally planned to evaluate the treatment of young wheezy children and 
to prevent recurrent obstructions, both being common, thus far unresolved issues in 
paediatrics. One hundred children younger than 2 years of age were recruited, most of 
them during their first wheezing episode. Background data were collected during the index 
wheezing episode in hospital, and follow-up data were collected during the prospectively 
scheduled follow-up visits, at 4.0, 7.2 and 12.3 years of median age. Only doctor-diagnosed 
asthma and other diseases were accepted. During this long-term follow-up study, the term 
bronchiolitis was originally used for index wheezing leading to hospitalisation at less than 
24 months of age. Currently, early childhood wheezing is the more proper term for virus-
induced wheezing in this age group, and it is used in the present thesis. 
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related to obesity is not equal to atopic asthma. This selected data give new information 
 
48 
 
about how obesity affects lung function in children who have suffered from wheezing 
provoked by infection in early childhood and are at risk of developing asthma. However, 
since obesity was strongly tracked from early school age to later school age, it was not 
possible to do any conclusions about the causality. The pulmonary function test results, 
both at early and later school age, gave opportunity to evaluate age differences in the 
influence of obesity. Atopic sensitisation was also possible to be estimated at both ages. 
 We used international references to define overweight and obesity, applying a 
British reference calculator for counting BMI-SDS. When starting the analyses of this thesis, 
the Finnish BMI-SDS curves based on national data were not available, but weight-for-
height definitions of childhood overweight and obesity were used. The weight-for-height 
definitions vary between preschool-aged and school-aged children and are not 
internationally used. The new Finnish age- and height-related, sex-specific BMI curves are 
now available (231). The prevalence of obesity, calculated by new references, has remained 
nearly the same in boys (4.7% earlier vs. 4.4% currently), but for girls, the new Finnish 
references give notably lower figures of obesity (3.2% vs. 1.8%) (79,231). Thus, the 
prevalence of obesity would have been slightly lower in the present data, if the new Finnish 
BMI-for-age curves would have been used. 
 The attendance rate at the age of 12.3 years was good, 81% among those 
participating in the intervention trial, although the follow-up time was long. In addition, 14 
children were hospitalised at the same time, and having fulfilled the inclusion criteria but 
refused to participate in the early intervention study, they attended the study visit at a later 
school age. This enables statistically relevant combined analyses in the BMD study. The 
follow-up data and entry to medical cards gave us reliable information about ICS use and 
other used corticosteroid medication. Nutritional, sport, and other lifestyle habits were not 
collected during the interview, which may have confounded the BMD results. 
 In the present study, no control group were recruited. One-third of the children 
had not been diagnosed as asthmatic, but only 21 children had never used any ICS; they 
were used as an internal control group in the BMD analyses. 
 In the BMD analyses, ICS use continuously or intermittent, more than 6 months 
was considered as a regular use. ICS medication for the prevention of recurrent wheezing 
in children at risk of asthma seldom continues for a long time; for asthma, it could continue 
through childhood. The overall ICS duration varied greatly, and therefore, we had 
difficulties to place the most appropriate time limit for regular use. We decided to use the 
shortest period used in previous studies to evaluate association between ICS and BMD, 
which has been 6 months (192-194). One aim of the study was to evaluate if there are age-
specific associations between ICS use and BMD. Many children need ICS at preschool age 
but “grow out” of the wheezing tendency at school age. Because of the limited number of 
asthma patients and the varying periods of ICS use, the ICS use was analysed only in two 
groups, under school aged and school-aged use. 
 The results of this study can be generalised to concern children who have 
suffered from severe early childhood wheezing. The BMD study results can be assumed 
also to reflect changes in BMD in other children using ICS medication. 
6.3.2 Strengths of the study 
The main strength of this prospective, longitudinal post-bronchiolitis study is the long 
follow-up time, up to the median age of 12.3 years and a high participation rate. The viral 
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aetiology of wheezing infection was verified and the atopic sensitisation was tested 
(50,216,218,245). The diagnosis of asthma and AD were based on medical examination and 
strict criteria (50,212,218). Weights and heights were measured at all control visits with 
objective standard methods, allowing a reliable longitudinal BMI monitoring. Risk factors 
were carefully evaluated in the previous studies from the same cohort, allowing a proper 
use of adjusted analyses. In addition, data on the important confounding factors, such as 
pubertal stage and systemic corticosteroid use, were available, together with basic 
demographic information. 
 Although data on the use of ICS were collected retrospectively, which can be 
considered as a weakness of the study, ICS use was recorded relatively accurately due to 
participation in the follow-up study. In Finland, the diagnosis of asthma and the 
prescription of medication for asthma are performed by a paediatrician; hence, diagnostic 
accuracy can be considered to be good. The researcher had access to all medical cards, in 
hospital and primary health care, to collect the ICS data and data on the systemic 
corticosteroid medications. 
6.3.3 Limitations of the study 
The small number of the patients is a main limitation of the study. The study was evidently 
underpowered to reveal all associations between the studied variables. In addition, the 
material of the study was selected lessening the generalizability of the results. On the other 
hand, the group consisting of children hospitalised for wheezing in early life is important in 
health care; their risk for later pulmonary disorders is increased, and therefore, the 
knowledge of potential risk factors like obesity is important particularly in them. 
 Another shortcoming in the BMD study was the lack of bone age measurement 
because the Tanner classification is not sufficiently exact in the estimation of pubertal stage 
in growth studies. Therefore, we were not able to evaluate the effects of ICS on growth in 
height. Physical activities and diets, including vitamin D and calcium intake, were not 
systematically recorded, which is also a clear shortcoming of the study. 
 The numbers of children in the present study were too small for any relevant sex-
specific analyses, which need to be counted as a shortcoming because sex is assumed to be one 
modifying factor between weight and asthma and atopic diseases. Also, results in previous BMD 
studies have been sex specific. 
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aetiology of wheezing infection was verified and the atopic sensitisation was tested 
(50,216,218,245). The diagnosis of asthma and AD were based on medical examination and 
strict criteria (50,212,218). Weights and heights were measured at all control visits with 
objective standard methods, allowing a reliable longitudinal BMI monitoring. Risk factors 
were carefully evaluated in the previous studies from the same cohort, allowing a proper 
use of adjusted analyses. In addition, data on the important confounding factors, such as 
pubertal stage and systemic corticosteroid use, were available, together with basic 
demographic information. 
 Although data on the use of ICS were collected retrospectively, which can be 
considered as a weakness of the study, ICS use was recorded relatively accurately due to 
participation in the follow-up study. In Finland, the diagnosis of asthma and the 
prescription of medication for asthma are performed by a paediatrician; hence, diagnostic 
accuracy can be considered to be good. The researcher had access to all medical cards, in 
hospital and primary health care, to collect the ICS data and data on the systemic 
corticosteroid medications. 
6.3.3 Limitations of the study 
The small number of the patients is a main limitation of the study. The study was evidently 
underpowered to reveal all associations between the studied variables. In addition, the 
material of the study was selected lessening the generalizability of the results. On the other 
hand, the group consisting of children hospitalised for wheezing in early life is important in 
health care; their risk for later pulmonary disorders is increased, and therefore, the 
knowledge of potential risk factors like obesity is important particularly in them. 
 Another shortcoming in the BMD study was the lack of bone age measurement 
because the Tanner classification is not sufficiently exact in the estimation of pubertal stage 
in growth studies. Therefore, we were not able to evaluate the effects of ICS on growth in 
height. Physical activities and diets, including vitamin D and calcium intake, were not 
systematically recorded, which is also a clear shortcoming of the study. 
 The numbers of children in the present study were too small for any relevant sex-
specific analyses, which need to be counted as a shortcoming because sex is assumed to be one 
modifying factor between weight and asthma and atopic diseases. Also, results in previous BMD 
studies have been sex specific. 
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7 Conclusions 
This prospective follow-up study had two focuses: the associations between weight status 
and asthma, atopy, and lung function during teenage years after hospitalisation for 
wheezing in infancy and the effect of ICS use during childhood on BMD in early 
adolescence. All children had suffered from severe bronchiolitis in infancy, about one-third 
of the patients had persistent asthma diagnosis later, and about one-fourth did not receive 
any corticosteroid medication during the follow-up time. 
 In the present study, there was no association between previous or current 
overweight or obesity and asthma or BHR at 7.2 or 12.3 years of (median) age. Overweight 
was associated with bronchial obstruction, as manifested by decreased FEV1/FVC at 7.2 
years and 12.3 years of age and decreased flows in small airways at 12.3 years of age. 
Overweight and obesity at early school age preceded reduced FEV1/FVC at age 12.3 years. 
Nevertheless, since overweight was highly persistent from early to late school age, the 
influence of previous and current overweight could not be assessed separately, and the 
present study could not estimate causality. Preliminary evidence was found that obesity 
may associate with a reduced risk of allergy at late school age, but the biological 
mechanism for this association is unknown and we could not estimate if there is any 
causality in this outcome either. 
 The BMD study revealed that the use of ICS during childhood may reduce 
BMD measured at teen age in children hospitalised for wheezing in infancy. High 
cumulative ICS doses were associated with reduced BMD in the femoral neck. Reduced 
BMD in the lumbar spine and in the femoral neck when apparent volumetric BMD was 
calculated was associated to regular ICS use before 6 years of age. Height-adjusted areal 
BMD and apparent volumetric BMD gave almost similar results. High cumulative doses 
during childhood were also associated with changes in volumetric BMD in the distal 
radius, including all its components: total, cortical, and trabecular bone. There were no 
significant associations between ICS use and BMD in tibia. The results remain similar when 
adjusted for known potential confounding factors: age, gender, pubertal stage, and weight 
status and use of systemic corticosteroids. 
 These results stress the importance of prevention of excessive weight gain in 
preschool-aged and school-aged children after early childhood wheezing. The prevention 
of overweight may prevent asthma and at least asthma-like symptoms. Asthma treatment 
with ICS can have detrimental effects on BMD. However, the clinical manifestations can 
occur later, in middle-aged adults or even in the elderly. Titrating ICS medication is 
recommended to the lowest possible dose to maintain asthma control. Also, proper asthma 
diagnosis with pulmonary function tests is important to target the needed long-term 
medication for children. Based on these preliminary results, we recommend considering the 
measurement of BMD in children with a long history of ICS medication, especially if they 
have other risk factors for low BMD.  
 Long-term follow-up studies are needed to clarify the complex connections and 
causality between asthma, allergic diseases, and weight. Further studies on how ICS during 
childhood affects adult BMD and bone mass are needed. 
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